Feb 25, 2021
Tricida Announces Fourth Quarter and Full Year 2020 Financial ResultsFeb 25, 2021
Alector Reports 2020 Fourth Quarter and Full Year Financial Results and Provides Business UpdateFeb 25, 2021
Tricida Provides Update on FDA InteractionsFeb 25, 2021
SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial UpdateFeb 25, 2021
Merck to Acquire Pandion TherapeuticsFeb 24, 2021
Aeglea BioTherapeutics Appoints Sara Brownstein to Board of DirectorsFeb 23, 2021
scPharmaceuticals Inc. Announces Results of Type A End-of-Review Meeting with FDA Regarding FUROSCIX® NDAFeb 22, 2021
Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific MeetingFeb 19, 2021
Adagio Therapeutics Announces Dosing of First Patient in Phase 1 Trial of ADG20, its Lead Monoclonal Antibody Candidate for the Treatment and Prevention of COVID-19Feb 18, 2021
EVOX THERAPEUTICS COMPLETES £69.2 MILLION SERIES C FINANCINGFeb 17, 2021
Corvus Pharmaceuticals Announces Closing of Public Offering of Common StockFeb 17, 2021
scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D., to its Board of DirectorsFeb 17, 2021
Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum ContagiosumFeb 17, 2021
Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene TherapyFeb 16, 2021
Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesFeb 16, 2021
Arcutis Biotherapeutics Announces Closing of Underwriters’ Over-Allotment Option in Connection with Public Offering of Common StockFeb 16, 2021
PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory BoardFeb 16, 2021
Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express ScriptsFeb 12, 2021
Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary SharesFeb 11, 2021
Fusion Pharmaceuticals Appoints Philina Lee, Ph.D., To Board Of DirectorsFeb 11, 2021
Decibel Therapeutics Announces Pricing of Initial Public OfferingFeb 10, 2021
Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic VariantsFeb 10, 2021
TERNS PHARMACEUTICALS, INC. ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING AND EXERCISE IN FULL OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARESFeb 10, 2021
Synlogic Appoints Lisa Kelly-Croswell to its Board of DirectorsFeb 8, 2021
Gemini Therapeutics Debuts as Publicly Traded Precision Medicine Company Focused on Age-Related Macular DegenerationFeb 8, 2021
FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment OptionsFeb 4, 2021
Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19Feb 4, 2021
CRINETICS PHARMACEUTICALS LEAD ACTH ANTAGONIST FOR CONGENITAL ADRENAL HYPERPLASIA AND CUSHING’S DISEASE (CRN04894)ADVANCES INTO PHASE 1 STUDYFeb 3, 2021
CRINETICS PHARMACEUTICALS ADVANCES CRN04777 FOR CONGENITAL HYPERINSULINISM INTO PHASE 1 STUDYFeb 3, 2021
VectivBio Announces First Patient Dosed in Pivotal Phase 3 Trial of Apraglutide for the Treatment of Short Bowel SyndromeFeb 2, 2021
Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPDFeb 1, 2021
Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque PsoriasisFeb 1, 2021
Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular AtrophyJan 28, 2021
Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin MutationsJan 26, 2021
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%Jan 26, 2021
VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq RulesJan 25, 2021
Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income CountriesJan 25, 2021
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s DiseaseJan 25, 2021
ASPEN NEUROSCIENCE ANNOUNCES APPOINTMENT OF DAMIEN MCDEVITT, PHD AS PRESIDENT AND CHIEF EXECUTIVE OFFICERJan 21, 2021
AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for ResidentsJan 21, 2021
VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) CompanyJan 21, 2021
Passage Bio Announces Pricing of Public OfferingJan 20, 2021
OmniGuide Receives 510(k) FDA Clearance for OTO-U Otology CO2 Surgical FiberJan 20, 2021
Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic DermatitisJan 20, 2021
IMARA ANNOUNCES THE APPOINTMENT OF KENNETH ATTIE, M.D. AS CHIEF MEDICAL OFFICERJan 19, 2021
Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology ConferenceJan 15, 2021
Valneva Announces Amendment to Deerfield and OrbiMed Debt Facility TermsJan 14, 2021
adMare Launches Abdera with AbCellera as a Founding PartnerJan 14, 2021
Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19Jan 14, 2021
Dr. Han Myint Appointed as NextCure’s Chief Medical OfficerJan 14, 2021
Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021Jan 14, 2021
Augmedix Launches Tech-Enabled Service Within Emergency Departments to Provide Real-Time Support and Optimize Clinician WorkflowsJan 13, 2021
Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic DermatitisJan 13, 2021
HARPOON THERAPEUTICS GRANTED ORPHAN DRUG DESIGNATION FROM FDA FOR HPN217 FOR TREATMENT OF MULTIPLE MYELOMAJan 12, 2021
TERNS COMPLETES ENROLLMENT IN PHASE 2A CLINICAL TRIAL OF TERN-101 IN NASH PATIENTSJan 12, 2021
Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple CancersJan 12, 2021
Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesJan 12, 2021
Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine CandidateJan 11, 2021
HARPOON THERAPEUTICS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCKJan 11, 2021
Turning Point and Zai Lab Broaden CollaborationJan 11, 2021
Turning Point Therapeutics Announces 2021 Milestone TargetsJan 11, 2021
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 MilestonesJan 11, 2021
Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesJan 11, 2021
Matthew Moore Joins Arcutis as Chief Business OfficerJan 11, 2021
Synlogic Outlines Upcoming Clinical MilestonesJan 8, 2021
Galecto Appoints Anne Prener to its Board of DirectorsJan 7, 2021
Kala Pharmaceuticals Announces Availability of EYSUVIS� for the Treatment of Dry Eye Disease and Provides Update on Development PipelineJan 7, 2021
Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second Quarter 2021Jan 7, 2021
Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for the Treatment of Dry Age-Related Macular Degeneration (AMD) in Patients with Complement Factor H (CFH) Loss of Function Gene VariantsJan 6, 2021
CRINETICS PHARMACEUTICALS?TO?REVIEW 2020 ACCOMPLISHMENTS AND PROVIDE 2021 PLANS AT 39TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCEJan 6, 2021
Alpine Immune Sciences Announces Executive Leadership Addition and PromotionJan 6, 2021
TigerConnect Acquires Critical Alert, Ends 2020 with Second Major AcquisitionJan 6, 2021
IMARA REPORTS PHASE 2A CLINICAL TRIAL RESULTS OF IMR-687 IN ADULT PATIENTS WITH SICKLE CELL DISEASEJan 5, 2021
MBX Biosciences Appoints Mary Jane Geiger, M.D., Ph.D., as Chief Medical OfficerJan 5, 2021
Ikena Oncology Closes $120 Million Series B Financing Led by Omega FundsJan 5, 2021
89bio Provides Business Outlook for 2021Jan 5, 2021
TELA Bio Appoints Renowned Surgeon as Vice President of Clinical DevelopmentJan 5, 2021
Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 TrialJan 5, 2021
TERNS CLOSES $87 MILLION SERIES C FINANCING TO ADVANCE NASH PORTFOLIOJan 5, 2021
TERNS APPOINTS THREE NEW INDEPENDENT DIRECTORS TO ITS BOARDJan 4, 2021
Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 GangliosidosisJan 4, 2021
Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cellsJan 4, 2021
HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN328, AN ANTI-DLL3 T CELL ENGAGER FOR TREATMENT OF SMALL CELL LUNG CANCER AND OTHER DLL3-ASSOCIATED TUMORSJan 1, 2021
SCORPION THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $162 MILLION SERIES B FINANCINGDec 28, 2020
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater ChinaDec 23, 2020
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum ContagiosumDec 22, 2020
Q32 Bio Appoints Experienced Biopharmaceutical Leader Mark Iwicki as Chairman of Board of DirectorsDec 21, 2020
Arcutis Biotherapeutics Added to Nasdaq Biotechnology IndexDec 21, 2020
Keros Therapeutics Announces Addition to NASDAQ Biotechnology IndexDec 21, 2020
ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101Dec 17, 2020
Cullinan Oncology Completes $131.2 Million Series C FinancingDec 17, 2020
NextCure Provides Updates on NC318 Clinical ProgramDec 17, 2020
Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis ImperfectaDec 17, 2020
Decibel Therapeutics Announces DB-020 Has Been Granted Fast Track Designation by the U.S. Food and Drug AdministrationDec 17, 2020
Keros Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of DirectorsDec 17, 2020
Aeglea BioTherapeutics Appoints Alison Lawton to Board of DirectorsDec 16, 2020
Passage Bio Announces Gene Therapy Manufacturing Research and Development SiteDec 16, 2020
Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine CandidateDec 15, 2020
SpringWorks Therapeutics Announces Executive Leadership PromotionsDec 15, 2020
Mereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on agreements with Silicon Valley Bank and Kreos CapitalDec 15, 2020
Lilly Announces Agreement to Acquire Prevail TherapeuticsDec 15, 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020Dec 15, 2020
Harmony Biosciences Enrolls First Patient In Phase 2 Trial Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willi SyndromeDec 14, 2020
X4 Pharmaceuticals Appoints Diego Cadavid, M.D., as Chief Medical OfficerDec 14, 2020
Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and LymphomaDec 14, 2020
HLS Therapeutics Reports Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with Vascepa® (Icosapent Ethyl)Dec 14, 2020
BELLUS Health Announces First Patient Dosed in its Phase 2 BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus Associated with Atopic DermatitisDec 14, 2020
VectivBio Appoints Sandip Kapadia to its Board of DirectorsDec 11, 2020
Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN MutationsDec 11, 2020
Alpine Immune Sciences Appoints Natasha Hernday to Board of DirectorsDec 11, 2020
Galecto Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate UpdateDec 11, 2020
ESCAPE BIO APPOINTS EDWARD OWENS AND SCOTT MORRISON TO BOARD OF DIRECTORSDec 11, 2020
Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 TrialDec 10, 2020
Fusion Pharmaceuticals Initiates Multi-Dose Portion Of Phase 1 Trial Of FPI-1434 In Patients With Advanced Solid TumorsDec 10, 2020
Passage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 GangliosidosisDec 10, 2020
X4 Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of WHIM SyndromeDec 10, 2020
AbCellera Announces Pricing of Initial Public OfferingDec 10, 2020
Acutus Medical Announces CE Mark and European Launch of AcQCross™ Transseptal System, a Fully Integrated Family of Transseptal Crossing ProductsDec 9, 2020
Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day on December 9, 2020Dec 9, 2020
Synlogic Appoints Michael Heffernan to its Board of DirectorsDec 8, 2020
HARPOON THERAPEUTICS REPORTS CLINICAL PROGRESS ACROSS ALL FOUR TRITAC® PIPELINE DEVELOPMENT PROGRAMSDec 8, 2020
Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase InhibitorDec 8, 2020
Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy ProgramDec 8, 2020
Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters� Option to Purchase Additional SharesDec 8, 2020
Sonendo® Reaches 500,000 Patients Treated Milestone with the GentleWave® ProcedureDec 8, 2020
BELLUS Health Announces First Patient Dosed in its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic CoughDec 8, 2020
RayzeBio Completes $105M Series B Financing to Advance Targeted Radiopharmaceuticals for CancerDec 8, 2020
Tricida Announces Updates on Veverimer Development Program, Regulatory Status and New Patent Extending Protection through 2038Dec 7, 2020
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and ExpositionDec 7, 2020
IMARA PRESENTS IMR-687 PHASE 2A OPEN LABEL EXTENSION CASE REPORTS ON TWO PATIENTS WITH SICKLE CELL DISEASE AT THE 62ND ASH ANNUAL MEETING AND EXPOSITIONDec 7, 2020
Acutus Medical Launches AcQBlate® Force Sensing Ablation System in EuropeDec 7, 2020
Passage Bio Teams with Catalent to Start CGMP Manufacturing for Lead Gene Therapy ProductsDec 7, 2020
Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters� Option to Purchase Additional SharesDec 7, 2020
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at AES2020, the Virtual Annual Meeting of the American Epilepsy SocietyDec 7, 2020
Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute of Chemical Engineers Conference on Microbiome EngineeringDec 7, 2020
Sierra Oncology Announces Momelotinib Data for Intermediate / High-risk Myelofibrosis Patients with Lower Baseline Platelet CountsDec 7, 2020
scPharmaceuticals Inc. Receives Complete Response Letter from FDA for FUROSCIX�Dec 7, 2020
BELLUS Health Appoints Ramzi Benamar as Chief Financial OfficerDec 7, 2020
Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque PsoriasisDec 6, 2020
CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Potential Benefit in Preventing Acute GVHD at the 62nd American Society of Hematology MeetingDec 6, 2020
Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & ExpositionDec 5, 2020
Sierra Oncology Presents Long-term Overall Survival and Sustained Efficacy Outcomes Data for Momelotinib at ASH Annual MeetingDec 3, 2020
Pandion Therapeutics Appoints Katina Dorton to its Board of DirectorsDec 2, 2020
Valneva Announces Acceleration of Pediatric Development for Lyme Disease Vaccine CandidateDec 1, 2020
Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque PsoriasisDec 1, 2020
Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of DirectorsDec 1, 2020
Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of HomocystinuriaNov 30, 2020
Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal DementiaNov 30, 2020
CTI BioPharma Announces Publication of Article Highlighting Pacritinib Data from the PAC203 Phase 2 Study in Myelofibrosis in Blood AdvancesNov 30, 2020
Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF BiomarkersNov 28, 2020
BHV3000-310 FPFV PRESS RELEASE DRAFT FOR REVIEWNov 23, 2020
PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53Nov 23, 2020
Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of DirectorsNov 23, 2020
Mereo BioPharma Appoints Suba Krishnan, M.D. Senior Vice President of Clinical DevelopmentNov 23, 2020
Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body PsoriasisNov 23, 2020
Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley BankNov 20, 2020
AbCellera-Discovered Antibody Granted Interim Authorization by Health Canada as a Treatment for COVID-19Nov 19, 2020
Peter Thiel Joins AbCellera�s Board of DirectorsNov 19, 2020
Ikena Oncology Assembles Multi-Disciplinary Scientific Advisory BoardNov 19, 2020
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic AcidemiaNov 18, 2020
Adagio Therapeutics COVID-19 Antibody Demonstrates Best-in-Class Breadth and Potency Against a Range of Coronaviruses that Pose Human ThreatNov 18, 2020
Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314Nov 18, 2020
AbCellera Expands Technology Stack with Acquisition of Trianni for $90 MillionNov 18, 2020
Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001Nov 17, 2020
ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNov 17, 2020
Verrica Pharmaceuticals Announces Receipt of Final FDA Minutes Following Type A Meeting Regarding Resubmission of the NDA for VP-102 in MolluscumNov 17, 2020
Keros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesNov 17, 2020
Augmedix Announces Third Quarter ResultsNov 17, 2020
IMARA ANNOUNCES THE APPOINTMENT OF LYNETTE HOPKINSON AS SENIOR VICE PRESIDENT OF REGULATORYNov 17, 2020
HLS Therapeutics Announces Health Canada Approval of PERSERIS� for the Treatment of SchizophreniaNov 16, 2020
CRINETICS PHARMACEUTICALS APPOINTS ACROMEGALY EXPERT, PETER TRAINER, VICE PRESIDENT OF CLINICAL ENDOCRINOLOGYNov 16, 2020
scPharmaceuticals Inc. Reports Third Quarter 2020 Financial Results and Provides Business UpdateNov 16, 2020
Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVIS™ for the Treatment of Dry Eye DiseaseNov 16, 2020
Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business UpdateNov 13, 2020
89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD’s The Liver Meeting® 2020Nov 13, 2020
Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical StudyNov 13, 2020
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate HighlightsNov 13, 2020
NextCure Reports Third Quarter 2020 Financial ResultsNov 13, 2020
Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business HighlightsNov 12, 2020
Acutus Medical Reports Third Quarter 2020 ResultsNov 12, 2020
Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Recent Corporate DevelopmentsNov 12, 2020
Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational UpdatesNov 12, 2020
BELLUS Health Reports Third Quarter 2020 Financial Results and Business HighlightsNov 12, 2020
HARPOON THERAPEUTICS PRESENTS ENCOURAGING PRECLINICAL DATA FOR HPN601 EPCAM PROTRITAC™ PROGRAM AT 35TH SITC ANNUAL MEETINGNov 12, 2020
Alpine Immune Sciences Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateNov 12, 2020
Steven Mickelsen, MD, Joins Acutus Medical as Chief Translational Science OfficerNov 12, 2020
SpringWorks Therapeutics Reports Third Quarter 2020 Financial Results and Recent Business HighlightsNov 11, 2020
Edgewise Therapeutics Initiates Phase 1 Clinical Trial of EDG-5506 in Becker Muscular DystrophyNov 11, 2020
Passage Bio Highlights University of Pennsylvania’s Gene Therapy Program’s Newly Published Research to Prevent Toxicity Associated with Gene TherapyNov 11, 2020
TELA Bio Announces Third Quarter 2020 Financial ResultsNov 10, 2020
Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results And Business UpdateNov 10, 2020
Prelude Therapeutics Announces Third Quarter 2020 Financial ResultsNov 10, 2020
89bio Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateNov 10, 2020
CTI BioPharma Reports Third Quarter 2020 Financial ResultsNov 10, 2020
Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)Nov 10, 2020
Adagio Therapeutics Raises $80M Series B Round to Further Advance Best-In-Class Antibodies for Coronavirus Treatment and PreventionNov 10, 2020
Aerpio Reports Third Quarter 2020 Financial Results and Provides Business UpdateNov 10, 2020
Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business HighlightsNov 10, 2020
Alector Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateNov 10, 2020
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial ResultsNov 9, 2020
Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1Nov 9, 2020
Verrica Pharmaceuticals Reports Third Quarter 2020 Financial ResultsNov 9, 2020
Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual MeetingNov 9, 2020
AbCellera-Discovered Antibody Receives U.S. FDA Emergency Use Authorization as a Monotherapy for the Treatment of COVID-19Nov 9, 2020
Tricida Announces Third Quarter 2020 Financial ResultsNov 6, 2020
CRINETICS PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATENov 5, 2020
Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateNov 5, 2020
ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational UpdateNov 5, 2020
Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate UpdatesNov 5, 2020
X4 Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateNov 5, 2020
Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate HighlightsNov 5, 2020
Adicet Reports Third Quarter 2020 Financial Results and Provides Business UpdateNov 5, 2020
Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateNov 5, 2020
Arcutis Announces Third Quarter 2020 Financial Results and Provides Business UpdateNov 5, 2020
Sierra Oncology Reports Third Quarter 2020 ResultsNov 5, 2020
IMARA REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTSNov 5, 2020
Merck to Acquire VelosBioNov 5, 2020
Synlogic Reports Third Quarter 2020 Financial Results and Provides Business UpdateNov 4, 2020
Synlogic Initiates Phase 1 Study of SYNB8802 for the Treatment of Enteric HyperoxaluriaNov 4, 2020
HARPOON THERAPEUTICS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATENov 4, 2020
Arcutis Announces Appointment of Terrie Curran to Board of DirectorsNov 4, 2020
VectivBio Strengthens Business Development Capabilities with Key AppointmentsNov 3, 2020
HARPOON THERAPEUTICS APPOINTS OMER SIDDIQUI AS VP DEVELOPMENT OPERATIONS AND PROJECT MANAGEMENTNov 2, 2020
Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEONov 2, 2020
Alector Provides Update on Arbitration Proceedings with Dr. Asa AbeliovichNov 2, 2020
Arcutis Biotherapeutics Presents New Positive Data from Phase 2 Studies of ARQ-151 (Topical Roflumilast Cream) in Chronic Plaque Psoriasis and Atopic DermatitisNov 2, 2020
Fusion Pharmaceuticals Announces Collaboration With AstraZeneca To Develop And Commercialize Next-Generation Radiopharmaceuticals And Combination TherapiesNov 2, 2020
Fusion Pharmaceuticals Appoints Barbara Duncan As Chairperson Of The Board Of DirectorsNov 2, 2020
X4 Pharmaceuticals Appoints Art Taveras, Ph.D., as Chief Scientific OfficerOct 29, 2020
AbCellera and Kodiak Sciences Enter Second Antibody Discovery Collaboration for Ophthalmology TargetsOct 29, 2020
Turning Point Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common StockOct 29, 2020
Edgewise Therapeutics Appoints John Moore as General CounselOct 29, 2020
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020Oct 29, 2020
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial ResultsOct 29, 2020
Tricida Provides Update on FDA InteractionsOct 28, 2020
Galecto Announces Pricing of Initial Public OfferingOct 28, 2020
GentiBio Expands Leadership Team and Partnership with MIGAL to Help Advance Development of Engineered Regulatory T Cell TherapiesOct 28, 2020
Passage Bio’s PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe DiseaseOct 27, 2020
Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye DiseaseOct 27, 2020
Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher DiseaseOct 27, 2020
MBX Biosciences Appoints James Cornelius to its Board of DirectorsOct 26, 2020
Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19Oct 26, 2020
Passage Bio’s PBGM01 Receives Orphan Drug Designation from EMA for Treatment of GM1 GangliosidosisOct 26, 2020
ESSA PHARMA INC. ANNOUNCES DELISTING FROM THE TSX-VOct 26, 2020
CRINETICS PHARMACEUTICALS ANNOUNCES PHASE 2 ACROBAT EDGE STUDY WITH PALTUSOTINE IN ACROMEGALY MET PRIMARY ENDPOINTOct 26, 2020
Arcutis Completes Enrollment in Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand EczemaOct 26, 2020
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics’ FAAH Inhibitor ProgramOct 26, 2020
Adicet Appoints Don Healey, Ph.D., as Chief Technology OfficerOct 26, 2020
Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of HomocystinuriaOct 24, 2020
Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR SymposiumOct 22, 2020
Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin’s lymphomaOct 22, 2020
BELLUS Health Closes US$40 Million Public Offering of Common Shares in Canada and the United States, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesOct 22, 2020
Edgewise Therapeutics Appoints Behrad Derakhshan as Chief Business OfficerOct 20, 2020
Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)Oct 20, 2020
Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory AffairsOct 20, 2020
Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic AcidemiaOct 20, 2020
Valneva Announces Positive Initial Results for Second Phase 2 Study of Lyme Disease Vaccine Candidate VLA15Oct 19, 2020
Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)Oct 19, 2020
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor ProgramOct 19, 2020
VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid TumorsOct 16, 2020
IMARA ANNOUNCES FIRST PATIENT DOSED IN FORTE PHASE 2B CLINICAL TRIAL OF IMR-687 IN BETA-THALASSEMIAOct 16, 2020
Valneva�s Chikungunya Vaccine Candidate Awarded EMA Prime DesignationOct 16, 2020
Edgewise Therapeutics Appoints Michael Carruthers as Chief Financial OfficerOct 15, 2020
Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular DegenerationOct 15, 2020
VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare DiseasesOct 13, 2020
Harmony Biosciences Receives FDA Approval For Expanded Use Of Wakix� (pitolisant) For The Treatment Of Cataplexy In Adult Patients With NarcolepsyOct 13, 2020
Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)Oct 13, 2020
PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C MutationOct 13, 2020
SpringWorks Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesOct 13, 2020
CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe ThrombocytopeniaOct 13, 2020
Passage Bio Announces Publication of Preclinical Data That Show Single Injection of Optimized AAV Vector into Cerebral Spinal Fluid Corrects Neurological Disease, Supporting Advancement of PBGM01 into ClinicOct 8, 2020
Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for EpilepsyOct 8, 2020
scPharmaceuticals Provides Business UpdateOct 8, 2020
Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE Before Year-EndOct 8, 2020
Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA NephropathyOct 8, 2020
TigerConnect Closes $45M Series D To Meet Soaring DemandOct 8, 2020
X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM SyndromeOct 7, 2020
VYNE Therapeutics Announces Covered Status for ZILXI� (minocycline) with Express ScriptsOct 6, 2020
Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common StockOct 6, 2020
Augmedix Closes $25 Million Private PlacementOct 5, 2020
New Data from Corvus Phase 1 Study of CPI-006 Continues to Support its Potential as a Treatment for COVID-19Oct 5, 2020
SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF?06863135 in Patients with Relapsed or Refractory Multiple MyelomaOct 5, 2020
Corvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in ChinaOct 1, 2020
VYNE Therapeutics Announces ZILXI� (minocycline) topical foam, 1.5% is Available in Pharmacies Nationwide Today, October 1stOct 1, 2020
X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison LawtonOct 1, 2020
Xtant Medical Announces Closing of Debt RestructuringSep 30, 2020
HLS Therapeutics Acquires Portfolio of Four Royalty InterestsSep 30, 2020
Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory GoutSep 29, 2020
Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic DermatitisSep 29, 2020
Fusion Pharmaceuticals Appoints Maria Stahl As Chief Legal OfficerSep 28, 2020
BIOSHIN, BIOHAVEN'S ASIA-PACIFIC SUBSIDIARY, RAISES $60M IN SERIES A FUNDING TO ADVANCE NEUROSCIENCE PIPELINE IN ASIA-PACIFIC REGIONSep 28, 2020
Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon™ PTH in Adult HypoparathyroidismSep 28, 2020
Mereo BioPharma Announces Changes to Board of DirectorsSep 25, 2020
TELA Bio Presents Additional Data from BRAVO Study of OviTex® for Ventral Hernia RepairSep 25, 2020
Graybug Appoints Three New Members to its Board of DirectorsSep 25, 2020
Galecto Raises $64 Million to Accelerate Development of Clinical PipelineSep 24, 2020
Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis ImperfectaSep 24, 2020
PMV Pharma Announces Pricing of Initial Public OfferingSep 24, 2020
AbCellera and IGM Biosciences Announce Multi-Year Antibody Discovery CollaborationSep 24, 2020
Graybug Vision Announces Pricing of Upsized Initial Public OfferingSep 23, 2020
Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPDSep 23, 2020
Ascendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH for Pediatric Growth Hormone Deficiency in JapanSep 23, 2020
AMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) TrialsSep 23, 2020
First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory GoutSep 23, 2020
Silverback Therapeutics Raises $85 Million in Series C Financing; Company Announces Executive PromotionsSep 21, 2020
Intended Delisting and Cancellation of Ordinary Shares from Trading on AIMSep 21, 2020
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple MyelomaSep 21, 2020
CRINETICS PHARMACEUTICALS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM FDA FOR CRN04777 FOR THE TREATMENT OF CONGENITAL HYPERINSULINISMSep 18, 2020
SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple MyelomaSep 17, 2020
Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia ProgramSep 17, 2020
New Data from Ciforadenant Phase 1b/2 Clinical Study Presented at ESMO Virtual Congress 2020Sep 17, 2020
ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020Sep 17, 2020
Acutus Medical Reports Second Quarter 2020 Financial ResultsSep 17, 2020
Acutus Medical Announces FDA Clearance of Second-Generation AcQMap 3D Imaging & Mapping CatheterSep 16, 2020
SpringWorks Therapeutics Announces Collaboration with Children’s Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat in Pediatric Patients with Desmoid Tumors and Reports Publication of Nirogacestat Case Series in Pediatric/Young Adult Desmoid Tumor PatientsSep 16, 2020
Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary DiseaseSep 16, 2020
89bio Announces Pricing of Upsized Public Offering of Common StockSep 16, 2020
Adicet Bio Appoints Nick Harvey as Chief Financial OfficerSep 16, 2020
Interim Data Reported for AbCellera-Discovered COVID-19 Antibody in Phase 2 Clinical TrialsSep 16, 2020
Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque PsoriasisSep 15, 2020
VectivBio Appoints Nader N. Youssef, M.D., as Senior Vice President, Head of Global Clinical Development and Medical AffairsSep 15, 2020
Adicet Announces Completion of Merger with resTORbioSep 15, 2020
Compass Therapeutics, Inc. Provides Corporate UpdateSep 15, 2020
Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma TrialSep 15, 2020
Galecto’s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase I Clinical Data Presented Recently at Several Scientific ConferencesSep 14, 2020
NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of DirectorsSep 14, 2020
ESCAPE BIO CLOSES $73 MILLION IN CROSSOVER FINANCING TO ADVANCE CLINICAL DEVELOPMENT OF PRECISION NEUROLOGY MEDICINES FOR GENETIC NEURODEGENERATION – ESCAPE BIOSep 14, 2020
89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASHSep 14, 2020
Valneva Announces Major COVID-19 Vaccine Partnership with U.K. GovernmentSep 14, 2020
Synlogic Appoints David Hava, Ph.D., as Chief Scientific OfficerSep 14, 2020
ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate CancerSep 14, 2020
SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple MyelomaSep 11, 2020
Corvus Pharmaceuticals Appoints Edith Mitchell, M.D., to Board of DirectorsSep 11, 2020
Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual MeetingSep 10, 2020
Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid ServicesSep 10, 2020
Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular DegenerationSep 10, 2020
Prevail Therapeutics Announces Appointment of William H. Carson, M.D., to Board of DirectorsSep 10, 2020
Corvus Pharmaceuticals Provides Update on Clinical Trial of CPI-006 for Patients with COVID-19Sep 9, 2020
Kinnate Biopharma Appoints Dean J. Mitchell as Chairman of the BoardSep 9, 2020
Adagio Therapeutics Strengthens Management Team with Appointments of Eric Kimble as Chief Commercial Officer and Ed Campanaro as SVP of Clinical OperationsSep 9, 2020
Valneva Announces New IXIARO® Supply Contract with the US Government worth up to $166 millionSep 9, 2020
Cleave Therapeutics Announces Preclinical Research Collaboration with Jazz Pharmaceuticals in Acute Myeloid Leukemia (AML)Sep 8, 2020
Ascendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon™ hGH for Treatment of Pediatric Growth Hormone DeficiencySep 8, 2020
VelosBio Appoints Paul Bavier as General CounselSep 8, 2020
Acutus Medical Announces Pulsed Field Ablation Program and Initial Pre-Clinical ResultsSep 8, 2020
PMV Pharma Appoints Laurie Stelzer to the Board of Directors and Robert Ticktin as General CounselSep 8, 2020
Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate VLA1553Sep 8, 2020
BELLUS Health Announces Design for its Phase 2b Trial with BLU-5937 in Refractory Chronic CoughSep 8, 2020
Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19Sep 8, 2020
Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE TherapeuticsSep 8, 2020
Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDASep 4, 2020
Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon™ hGH for Pediatric Growth Hormone Deficiency (GHD)Sep 4, 2020
Graybug Vision Appoints Robert Breuil as Chief Financial OfficerSep 4, 2020
CRINETICS PHARMACEUTICALS PROVIDES NEW DATA FROM PALTUSOTINE AND ACTH ANTAGONIST DEVELOPMENT PROGRAMS AT EUROPEAN CONGRESS OF ENDOCRINOLOGYSep 3, 2020
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement Priced At-The-Market of Common Shares and 15-Month Purchase Warrants for Potential Additional Gross Proceeds of $23.9 MillionSep 3, 2020
CRINETICS PHARMACEUTICALS APPOINTS RARE DISEASE EXECUTIVE, CAMILLE L. BEDROSIAN, M.D., TO BOARD OF DIRECTORSSep 3, 2020
89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe HypertriglyceridemiaSep 2, 2020
X4 Pharmaceuticals Announces Publication of Mavorixafor Phase 2 Clinical Data for Treatment of WHIM Syndrome in ‘Blood’ - the Official Journal of the American Society of HematologySep 1, 2020
Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley BankSep 1, 2020
Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 PatientsSep 1, 2020
TigerConnect Acquires Call Scheduler, Launches Fully-Integrated TigerSchedule™ to Simplify Physician On-Call SchedulingAug 31, 2020
NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS® System for Refractory EpilepsyAug 31, 2020
VelosBio Announces FDA Fast Track and Orphan Drug Designations for VLS-101 in Patients with Mantle Cell LymphomaAug 31, 2020
Pandion Reports Second Quarter 2020 Financial Results and Provides Business UpdateAug 31, 2020
Turning Point Therapeutics Announces Scientific Advisory BoardAug 27, 2020
Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary FibrosisAug 27, 2020
Gemini Therapeutics Appoints Dr. Tuyen Ong as Independent DirectorAug 26, 2020
Harpoon Therapeutics Names Karin Ann Thacker, M.Sc., VP Regulatory Affairs and Quality AssuranceAug 26, 2020
Silverback Therapeutics Initiates Phase 1 Clinical Study of SBT6050Aug 26, 2020
Kinnate Biopharma Closes $98 Million Series C FinancingAug 25, 2020
Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell DiseaseAug 25, 2020
Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory DiseaseAug 25, 2020
ReViral Raises $44 Million in Series C FinancingAug 24, 2020
Prelude Therapeutics Announces Closing of $50M Series C FinancingAug 24, 2020
Xtant Medical Announces U.S. Commercial Launch of the Matriform� Si for Spinal Fusion ProceduresAug 24, 2020
Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid TumorsAug 24, 2020
Tricida Receives Complete Response Letter from the FDA for its New Drug Application for Veverimer for the Treatment of Metabolic Acidosis and Slowing of Kidney Disease Progression in Patients with Metabolic Acidosis Associated with CKDAug 24, 2020
Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor ModelsAug 21, 2020
Harmony Biosciences Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional SharesAug 20, 2020
AbCellera Acquires OrthoMab Bispecific Platform to Propel the Development of Antibody Therapies for Pharma and Biotech PartnersAug 19, 2020
Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPDAug 19, 2020
Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib, Provides Regulatory UpdateAug 18, 2020
Ikena Oncology Appoints Dr. Sergio Santillana, MD, MSc, MBA as Chief Medical OfficerAug 17, 2020
Aerin Medical Announces Appointment of Matt Brokaw as President and CEO and Closing of $48MM Equity FinancingAug 17, 2020
Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial OfficerAug 14, 2020
Imara Reports Second Quarter 2020 Financial Results and Business HighlightsAug 14, 2020
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020Aug 13, 2020
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial ResultsAug 13, 2020
89bio Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateAug 13, 2020
Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell DiseaseAug 13, 2020
BELLUS Health Reports Second Quarter 2020 Financial Results and Business HighlightsAug 13, 2020
Passage Bio Reports Second Quarter 2020 Financial Results and Recent Business HighlightsAug 13, 2020
scPharmaceuticals Inc. Reports Second Quarter 2020 Financial Results and Provides Business UpdateAug 12, 2020
Ikena Oncology Announces Publication in Nature Communications of Preclinical Data Supporting the Therapeutic Potential of AHR BlockadeAug 12, 2020
Aerpio Reports Second Quarter 2020 Financial Results and Provides Business UpdateAug 12, 2020
TELA Bio Announces Second Quarter 2020 Financial ResultsAug 12, 2020
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ CNP for the Treatment of Achondroplasia in EuropeAug 12, 2020
SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business HighlightsAug 11, 2020
Alpine Immune Sciences Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateAug 11, 2020
Press Release: Bayer to Acquire UK-Based KaNDy TherapeuticsAug 11, 2020
Fusion Pharmaceuticals Announces Second Quarter 2020 Financial Results And Business UpdateAug 11, 2020
KaNDY Therapeutics to be acquired by Bayer AG for up to $1.5 billionAug 11, 2020
Verrica Pharmaceuticals Licenses LTX-315, A First-in-Class Oncolytic Peptide Based Immunotherapy, from Lytix Biopharma AS, for the Treatment of Dermatologic Oncology IndicationsAug 11, 2020
Alector Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateAug 11, 2020
Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business HighlightsAug 11, 2020
Arcutis Announces Second Quarter 2020 Financial Results and Provides Business UpdateAug 10, 2020
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate HighlightsAug 10, 2020
Terns Appoints Senthil Sundaram as Chief Executive Officer, Mark Vignola, PhD, as Chief Financial Officer, and Erink Quirk, M.D. as PresidentAug 10, 2020
Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational UpdatesAug 10, 2020
Keros Therapeutics to be Featured on The Balancing Act's """"Behind the Mystery"""" Rare Disease SeriesAug 10, 2020
Acutus Medical Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesAug 7, 2020
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateAug 6, 2020
CTI BioPharma Reports Second Quarter 2020 Financial ResultsAug 6, 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020Aug 6, 2020
ObsEva Announces Second Quarter 2020 Financial Results and Business UpdateAug 6, 2020
Glaukos Corporation Announces Second Quarter 2020 Financial ResultsAug 6, 2020
Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate UpdatesAug 6, 2020
Sierra Oncology Reports Second Quarter 2020 ResultsAug 6, 2020
Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateAug 6, 2020
Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate UpdatesAug 6, 2020
Synlogic Reports Second Quarter 2020 Financial Results and Provides Business UpdateAug 6, 2020
Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateAug 6, 2020
NextCure Reports Second Quarter 2020 Financial ResultsAug 6, 2020
Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for MomelotinibAug 5, 2020
Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateAug 5, 2020
Tricida Announces Second Quarter 2020 Financial ResultsAug 5, 2020
GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory DiseasesAug 5, 2020
ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational UpdateAug 5, 2020
Verrica Pharmaceuticals Reports Second Quarter 2020 Financial ResultsAug 5, 2020
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati TherapeuticsAug 5, 2020
Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in JapanAug 5, 2020
Adicet Bio Receives $10 Million Product Development Milestone From RegeneronAug 5, 2020
Acutus Medical Announces Pricing of Initial Public OfferingAug 4, 2020
Bethany Dudek Joins Arcutis as Vice President of QualityAug 4, 2020
Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of ARDS in Patients with Moderate to Severe COVID-19Aug 4, 2020
Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program UpdateAug 4, 2020
ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus InfectionAug 3, 2020
PMV Pharma Closes $70 Million in Series D FinancingAug 3, 2020
VelosBio Appoints Dr. Enoch Kariuki as Chief Financial OfficerAug 3, 2020
Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical OfficerAug 3, 2020
Dr. Rich Heyman appointed as Chair of the Board of Directors of PMV PharmaAug 3, 2020
The Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque PsoriasisAug 3, 2020
Graybug Vision Appoints Leading Ophthalmologists and Retinal Experts to Join Its Scientific Advisory BoardAug 3, 2020
AbCellera Provides COVID-19 Program Update with the Start of Phase 3 Clinical Trials and the Expansion of its COVID-19 Antibody DatabaseAug 3, 2020
Aspen Neuroscience Announces Management TransitionJul 31, 2020
Stereotaxis and Acutus Medical Announce First Integrated Cardiac Ablation Procedure with TeleRobotic SupportJul 31, 2020
Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque PsoriasisJul 30, 2020
Terns Announces Completion and Positive Results From Phase 1 Clinical Trial of TERN-201, A SSAO Inhibitor in Development for NASHJul 30, 2020
X4 Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateJul 30, 2020
Synlogic Announces Promotion of Antoine 'Tony' Awad to Chief Operating Officer and Additions to Leadership TeamJul 30, 2020
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial ResultsJul 30, 2020
resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial ResultsJul 30, 2020
Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-ThalassemiaJul 29, 2020
Imara Added to Membership of U.S. Small-Cap Russell 2000® IndexJul 28, 2020
Sierra Oncology Appoints Christina Thomson as General CounselJul 28, 2020
Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal DementiaJul 28, 2020
Cleave Therapeutics Announces Commencement of Phase 1 Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)Jul 28, 2020
NABRIVA Receives European Approval for XENLETA® (lefamulin) for Treatment of Community-Acquired Pneumonia (CAP)Jul 28, 2020
ESSA Pharma Announces Proposed Public Offering of Common SharesJul 28, 2020
Terns and Hanson Pharma Announce Collaboration and License Agreement for TNR-000632 in Greater ChinaJul 28, 2020
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000Jul 28, 2020
resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older AdultsJul 28, 2020
Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory GoutJul 27, 2020
New Published Data Show NeuroPace’s RNS® System Provides Patients with Unprecedented Seizure Reduction and Improved Quality of LifeJul 27, 2020
MBX Biosciences Closes $34.6 Million Series A Financing in Rare Endocrine DiseasesJul 22, 2020
Closing of Financing, Issued Share Capital and Total Voting RightsJul 22, 2020
Scientific Summary: Cyrus NextGen Antibody structure prediction beats Schrodinger and others in a large independent benchmarkJul 22, 2020
Valneva Announces Positive Initial Results for Phase 2 Study of Lyme Disease Vaccine CandidateJul 22, 2020
SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid TumorsJul 21, 2020
New Cyrus “NextGen” antibody software outperforms the competition in third party test with BIOCAD biotechnologyJul 21, 2020
AbCellera Announces Agreement with Alloy Therapeutics to Integrate Access to ATX-Gx™ Humanized Mice Platform for Antibody Discovery ProgramsJul 20, 2020
Valneva Confirms Participation in UK Government COVID-19 Vaccine Response ProgramJul 20, 2020
Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp PsoriasisJul 20, 2020
HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa® (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory priceJul 16, 2020
Adimab Spins Out Adagio Therapeutics to Develop Broadly Protective Coronavirus AntibodiesJul 16, 2020
XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired PneumoniaJul 15, 2020
Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S.Jul 15, 2020
Tricida Provides Regulatory Update on VeverimerJul 15, 2020
ObsEva SA Awarded Clinical Science Award for Oral Presentation at ESHRE Virtual 36th Annual Meeting, July 2020Jul 15, 2020
ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate CancerJul 15, 2020
The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque PsoriasisJul 14, 2020
Verrica Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for VP-102 for the Treatment of Molluscum ContagiosumJul 13, 2020
Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand EczemaJul 13, 2020
89bio Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesJul 13, 2020
Use of Cyrus Bench cited in review article of human diseases caused by formin INF2 mutationsJul 13, 2020
Turning Point Therapeutics Names Andrew Partridge As Executive Vice President and Chief Commercial OfficerJul 13, 2020
NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical OfficerJul 10, 2020
scPharmaceuticals Appoints Sara Bonstein to Board of DirectorsJul 9, 2020
Inspire Medical Systems, Inc. Announces Appointment of Veteran Consumer Marketing Executive Georgia Garinois-Melenikiotou to its Board of DirectorsJul 9, 2020
TELA Bio Announces Interim Analysis from BRAVO Study of OviTex® for Ventral Hernia RepairJul 8, 2020
CRINETICS PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR PALTUSOTINE FOR THE TREATMENT OF ACROMEGALYJul 8, 2020
Kinnate Biopharma Appoints Dr. Richard Williams as Chief Medical OfficerJul 8, 2020
VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in OncologyJul 8, 2020
KLAS Rates TigerConnect Among Top Advanced Clinical Communication PlatformsJul 8, 2020
Edgewise Therapeutics Appoints Abby H. Bronson, M.B.A., as Vice President, Patient Advocacy and External InnovationJul 7, 2020
Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater ChinaJul 7, 2020
NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid TumorsJul 7, 2020
Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19Jul 6, 2020
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine FibroidsJul 6, 2020
BELLUS Health Announces Topline Results from its Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic CoughJul 6, 2020
Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation PlanJul 6, 2020
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSsJul 2, 2020
HARPOON THERAPEUTICS ANNOUNCES CHANGES TO BOARD OF DIRECTORSJul 1, 2020
scPharmaceuticals Announces FUROSCIX® NDA ResubmissionJul 1, 2020
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPAJun 30, 2020
WEP Clinical Partners With Nabriva Therapeutics For The Named Patient Supply Of Xenleta® (Lefamulin)Jun 30, 2020
TELA Bio Announces Closing of Public Offering of Common StockJun 30, 2020
Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and DevelopmentJun 29, 2020
Verrica Pharmaceuticals Provides Regulatory Update on VP-102Jun 29, 2020
IMARA ADDED TO MEMBERSHIP OF U.S. SMALL-CAP RUSSELL 2000® INDEXJun 26, 2020
Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone DeficiencyJun 26, 2020
Passage Bio Added to Russell 2000 IndexJun 25, 2020
Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002, a TREM2 Activating Antibody for the Treatment of Alzheimer’s Disease, in The Journal of Experimental MedicineJun 25, 2020
Fusion Pharmaceuticals Announces Pricing Of Initial Public OfferingJun 25, 2020
IMARA ANNOUNCES RECIPIENTS OF REAL IMPACT GRANTS PROGRAM TO SUPPORT PEOPLE AFFECTED BY RARE GENETIC BLOOD DISORDERSJun 24, 2020
IMARA RECEIVES ORPHAN DRUG DESIGNATION FOR IMR-687 FOR TREATMENT OF BETA-THALASSEMIAJun 24, 2020
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced MalignanciesJun 23, 2020
TELA Bio Announces Proposed Public Offering of Common StockJun 23, 2020
Gilead Sciences Secures Exclusive Option to Acquire Pionyr ImmunotherapeuticsJun 23, 2020
Gilead Sciences Secures Exclusive Option to Acquire Pionyr ImmunotherapeuticsJun 23, 2020
Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private PlacementJun 23, 2020
Repare Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesJun 22, 2020
BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical TrialJun 22, 2020
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple MyelomaJun 22, 2020
ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting IIJun 22, 2020
Ikena Oncology Presents New Preclinical Data Highlighting the Anti-Cancer Effects of TEAD Inhibition on the Hippo Signaling PathwayJun 22, 2020
Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 ?/? at AACR Virtual Annual Meeting 2020Jun 22, 2020
TELA Bio, Inc. to Join the Russell 2000® IndexJun 22, 2020
Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer ModelsJun 22, 2020
Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic DermatitisJun 22, 2020
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting IIJun 19, 2020
Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO™ (fosfomycin) for injectionJun 18, 2020
Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101Jun 18, 2020
Valneva and Bavarian Nordic Announce Marketing and Distribution PartnershipJun 18, 2020
Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular DiseasesJun 17, 2020
Edgewise Therapeutics Appoints Kirsten L. Gruis, M.D., M.S. as Chief Medical OfficerJun 16, 2020
Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next YearJun 16, 2020
Inspire Medical Systems, Inc. Announces Cigna Coverage for Inspire Therapy for the Treatment of Obstructive Sleep ApneaJun 15, 2020
Batavia Biosciences and Valneva Collaborate to Accelerate Development of Low-cost Inactivated Polio VaccineJun 15, 2020
Anthony Bihl Joins Sonendo® Board of DirectorsJun 15, 2020
Augmedix Announces New Board Member, Jennifer M. CarterJun 12, 2020
X4 Pharmaceuticals Presents Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome at EHA 2020Jun 12, 2020
Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual MeetingJun 12, 2020
Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for MomelotinibJun 12, 2020
Verrica Pharmaceuticals Announces Positive Results from Two New Pooled Analyses of the Phase 3 CAMP Trials of VP-102 in Molluscum ContagiosumJun 12, 2020
IMARA PRESENTS POSITIVE INTERIM RESULTS FROM PHASE 2A STUDY OF IMR-687 IN SICKLE CELL DISEASE AT THE VIRTUAL EUROPEAN HEMATOLOGY ASSOCIATION ANNUAL CONGRESSJun 11, 2020
Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory GoutJun 11, 2020
X4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific OfficerJun 11, 2020
CRINETICS PHARMACEUTICALS CONFIRMS COMPLETION FOR HALF OF THE ENROLLED PATIENTS IN THE ONGOING PHASE 2 ACROBAT EDGE CLINICAL TRIAL FOR PALTUSOTINEJun 10, 2020
Verrica Pharmaceuticals Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of DirectorsJun 9, 2020
ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of DirectorsJun 9, 2020
Pandion Therapeutics Announces Issuance of U.S. Patent for Bifunctional Molecules Derived from TALON™ PlatformJun 8, 2020
Glaukos Corporation Announces Pricing of Private Offering of $250 Million of 2.75% Convertible Senior NotesJun 8, 2020
Inspire Medical Systems, Inc. Announces Appointment of Medical Technology Industry Veteran Phil Ebeling as Chief Operating OfficerJun 8, 2020
Ascendis Pharma A/S Announces Participation in ENDO Online 2020Jun 8, 2020
Alpine Immune Sciences Provides Clinical Update of its Phase 1 Trial of ALPN-101 in Healthy Volunteers at the European League Against Rheumatism (EULAR) E-Congress 2020Jun 5, 2020
Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesJun 5, 2020
Menlo Therapeutics Announces Pricing of Offering of Common StockJun 4, 2020
89bio Appoints Veteran Finance Executive Lota Zoth to Board of DirectorsJun 4, 2020
Prevail Therapeutics Appoints Kira Schwartz, J.D., as General CounselJun 4, 2020
Silverback Therapeutics Appoints Vickie L. Capps to Board of Directors and Audit Committee ChairJun 4, 2020
Alpine Immune Sciences Presents Preclinical Data on Novel Dual BAFF/APRIL Inhibitory Domains for B cell Mediated Autoimmune Diseases at the European Congress of Rheumatology E-Congress 2020Jun 2, 2020
WAKIX® (pitolisant) Data from Harmony Bioscienes Included on American Academy of Neurology Science Highlights Virtual PlatformJun 2, 2020
Valneva Announces Publication in The Lancet of Complete Phase 1 Data for its Single-Shot Chikungunya Vaccine CandidateJun 2, 2020
Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne VulgarisJun 1, 2020
CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical TrialJun 1, 2020
HLS Therapeutics to Become Distributor of the Saladax MyCare� Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic ReagentsJun 1, 2020
Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat TumorsJun 1, 2020
Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based TreatmentsJun 1, 2020
Ayisha Jeter Joins Arcutis as Vice President of Market AccessJun 1, 2020
AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody TreatmentMay 29, 2020
HARPOON THERAPEUTICS PRESENTS INTERIM PHASE 1 DATA FROM AN ONGOING DOSE ESCALATION TRIAL FOR THE PSMA-TARGETING TRITAC® HPN424 AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAMMay 29, 2020
Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046May 29, 2020
ObsEva SA to present at the Jefferies Virtual Healthcare Conference June 3rd, 2020May 29, 2020
Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for RosaceaMay 29, 2020
NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual MeetingMay 29, 2020
Corvus Pharmaceuticals Presents Updated Clinical Data Supporting and Refining the Adenosine Gene Signature’s Ability to Identify Patients Likely to Respond to Treatment with CiforadenantMay 28, 2020
resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home ResidentsMay 27, 2020
Kinnate Biopharma Appoints Nima Farzan as Chief Executive OfficerMay 27, 2020
Turning Point Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common StockMay 27, 2020
CRINETICS PHARMACEUTICALS APPOINTS ADRIANA CABRÉ, MBA, AS VICE PRESIDENT OF HUMAN RESOURCESMay 27, 2020
resTORbio Provides Corporate Update and Reports First Quarter 2020 Financial ResultsMay 27, 2020
AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery PlatformMay 27, 2020
Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive ImmunityMay 27, 2020
Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and OperationsMay 27, 2020
Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 PatientsMay 26, 2020
KALA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR EYSUVIS™ FOR DRY EYE DISEASEMay 26, 2020
TransMedics Announces Positive Top-line Results from U.S. Pivotal OCS� Liver PROTECT TrialMay 26, 2020
TransMedics Announces Pricing of Public Offering of Common StockMay 26, 2020
SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of DirectorsMay 26, 2020
Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of NeurologyMay 26, 2020
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive OfficerMay 26, 2020
Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers SquibbMay 22, 2020
Tricida Announces Closing of Offering of $200 Million of 3.50% Convertible Senior Notes Due 2027, Including Full Exercise of Option to Purchase Additional NotesMay 22, 2020
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial ResultsMay 22, 2020
AbCellera Announces Multi-Year Antibody Discovery Collaboration with LillyMay 21, 2020
Synlogic Announces Termination of AbbVie Collaboration AgreementMay 21, 2020
Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate UpdateMay 21, 2020
Passage Bio Receives Rare Pediatric Disease Designation for PBGM01 for Patients with GM1 GangliosidosisMay 20, 2020
New Alliance Maps the Way in ElectrophysiologyMay 20, 2020
scPharmaceuticals Announces Pricing of Public Offering of Common StockMay 20, 2020
ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational ResultsMay 19, 2020
Ascendis Pharma A/S Reports First Quarter 2020 Financial ResultsMay 19, 2020
Pandion Therapeutics Appoints John S. Sundy, M.D., Ph.D., as Chief Medical OfficerMay 19, 2020
Galecto Appoints New Chair and Strengthens Board of DirectorsMay 18, 2020
National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 PercentMay 18, 2020
Graybug Vision Appoints Parisa Zamiri, Physician-Scientist with Deep Expertise in Ophthalmology, as Chief Medical OfficerMay 15, 2020
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual MeetingMay 14, 2020
X4 Pharmaceuticals Announces Data from Phase 2 Open-Label Extension Trial of Mavorixafor in WHIM Syndrome as Published in EHA AbstractMay 14, 2020
Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business HighlightsMay 14, 2020
BELLUS Health Reports First Quarter 2020 Financial Results and Business Highlights, and Provides Updates on BLU-5937May 14, 2020
Alpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company UpdateMay 14, 2020
Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical ProgramMay 13, 2020
Alector Reports 2020 First Quarter Financial Results and Business HighlightsMay 13, 2020
89bio Reports First Quarter 2020 Financial Results and Provides Corporate UpdateMay 12, 2020
scPharmaceuticals Inc. Reports First Quarter 2020 Financial Results and Provides Business UpdateMay 12, 2020
Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell TherapyMay 12, 2020
Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924)May 12, 2020
Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 ResponseMay 12, 2020
TELA Bio Announces First Quarter 2020 Financial ResultsMay 12, 2020
SpringWorks Therapeutics Reports First Quarter 2020 Financial Results and Recent Business HighlightsMay 12, 2020
Arcutis Announces First Quarter 2020 Financial Results and Provides Business UpdateMay 11, 2020
Nabriva Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate UpdatesMay 11, 2020
Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial OfficerMay 11, 2020
Passage Bio Reports First Quarter 2020 Financial Results and Recent Business HighlightsMay 11, 2020
Augmedix Introduces New Services that Increase Clinician Productivity and Enhance the Clinician-Patient RelationshipMay 8, 2020
CRINETICS PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEMay 8, 2020
Synlogic Reports First Quarter 2020 Financial Results and Provides Business UpdateMay 7, 2020
KALA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEMay 7, 2020
Aerpio Reports First Quarter 2020 Financial Results and Provides Business UpdateMay 7, 2020
Gemini Therapeutics Appoints Marc E. Uknis, MD, FACS as Chief Medical OfficerMay 7, 2020
IMARA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTSMay 7, 2020
Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate HighlightsMay 7, 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020May 7, 2020
Glaukos Corporation Announces First Quarter 2020 Financial ResultsMay 7, 2020
CTI BioPharma Reports First Quarter 2020 Financial ResultsMay 7, 2020
NextCure Reports First Quarter 2020 Financial ResultsMay 7, 2020
Sierra Oncology Reports First Quarter 2020 ResultsMay 7, 2020
X4 Pharmaceuticals Provides Corporate Update, Including Expected Impact of COVID-19, and Reports First Quarter 2020 Financial ResultsMay 7, 2020
Verrica Pharmaceuticals Reports First Quarter 2020 Financial ResultsMay 7, 2020
Intellia Therapeutics Announces First Quarter 2020 Financial ResultsMay 7, 2020
Tricida Announces First Quarter 2020 Financial ResultsMay 7, 2020
Passage Bio Announces Expansion of Gene Therapy Collaboration with University of PennsylvaniaMay 7, 2020
Selecta Biosciences Reports First Quarter 2020 Financial ResultsMay 6, 2020
Galecto Advances Phase 2b Study of GB0139 in Idiopathic Pulmonary Fibrosis; Recruitment Remains on Track Despite COVID-19 CrisisMay 6, 2020
IMARA LAUNCHES ‘REAL IMPACT’ COMMUNITY SUPPORT PROGRAM TO ADDRESS UNMET NEEDS AFFECTING PEOPLE WITH RARE GENETIC BLOOD DISORDERSMay 6, 2020
HARPOON THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEMay 5, 2020
Inspire Medical Systems, Inc. Announces First Quarter 2020 Financial ResultsMay 5, 2020
XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)May 5, 2020
ObsEva Announces First Quarter 2020 Financial Results and Business UpdateMay 4, 2020
Galecto presents GB0139 preclinical and clinical data on anti-fibrotic activity as online Experimental Biology 2020 posterMay 4, 2020
IMARA ANNOUNCES APPOINTMENT OF STEPHEN M. MIGAUSKY AS GENERAL COUNSELMay 3, 2020
AbCellera Receives $175.6 million from the Government of Canada to Discover Solutions for COVID-19 and Build a Manufacturing Facility for Antibody DrugsApr 30, 2020
Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15Apr 30, 2020
Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020Apr 30, 2020
Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesApr 30, 2020
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial ResultsApr 30, 2020
Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical OfficerApr 29, 2020
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy TechnologyApr 29, 2020
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy TechnologyApr 29, 2020
Aspen Neuroscience Announces Addition to Board of DirectorsApr 28, 2020
Gemini Therapeutics Appoints David Lubner as Independent DirectorApr 28, 2020
ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesApr 28, 2020
Selecta Biosciences Appoints Dr. Goran Ando to its Board of DirectorsApr 27, 2020
CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19Apr 27, 2020
Halley E. Gilbert Appointed to Arcutis Board of DirectorsApr 27, 2020
Galecto Appoints Jonathan Freve as Chief Financial OfficerApr 27, 2020
HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN217, A BCMA TARGETING TRITAC, FOR MULTIPLE MYELOMAApr 23, 2020
TELA Bio Announces Changes to its Board of DirectorsApr 23, 2020
Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.Apr 23, 2020
Menlo Therapeutics and Cutia Therapeutics Enter into Exclusive License Agreement for AMZEEQ™ and Approved Topical Minocycline Products in Greater ChinaApr 22, 2020
Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19Apr 22, 2020
Silverback Therapeutics Announces Appointment of Veteran Executive Laura Shawver, Ph.D. as President and CEOApr 21, 2020
Inspire Medical Systems Announces FDA Approval of Expanded Age Range for Inspire TherapyApr 21, 2020
Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand EczemaApr 21, 2020
Nature Communications Highlights Research by Scientists at Graybug Vision and Johns Hopkins University on Sustained Treatment of Retinal DiseasesApr 19, 2020
Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for HypoparathyroidismApr 17, 2020
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesApr 16, 2020
Inspire Medical Systems, Inc. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesApr 16, 2020
TigerConnect Launches TigerTouch Video and Voice Telehealth Features to Help Hospitals Combat COVID-19Apr 16, 2020
Clinical Cancer Research Highlights Potent Antitumor Activity of Repotrectinib in Treatment-Naïve and Solvent-Front Mutation Ros1-Positive Non-Small Cell Lung CancerApr 15, 2020
Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United StatesApr 15, 2020
Carl Gordon named to 2020 Forbes Midas List of top venture capitalistsApr 14, 2020
ObsEva to Increase Issued Share Capital by Creating Additional Treasury SharesApr 13, 2020
89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor AgonismApr 13, 2020
Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 PandemicApr 13, 2020
Inspire Medical Systems, Inc. Provides First Quarter and Full Year 2020 UpdateApr 13, 2020
NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 PandemicApr 9, 2020
Centers for Medicare & Medicaid Services Issues Product-Specific J-Code for XENLETAApr 9, 2020
Glaukos Provides Update on COVID-19 Impact and Preliminary Net Sales Range for the First Quarter of 2020Apr 8, 2020
Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)Apr 7, 2020
X4 Pharmaceuticals Showcases Strategic Focus on WHIM Syndrome During 2020 Analyst Day WebinarApr 7, 2020
Keros Therapeutics Announces Pricing of Initial Public Offering of Common StockApr 6, 2020
Aspen Neuroscience Announces Reconstitution of the Board of Directors with the Addition of Seasoned Industry ExecutivesApr 6, 2020
ObsEva SA Announces New Interim Chief Financial OfficerApr 6, 2020
CRINETICS PHARMACEUTICALS REPORTS POSITIVE INTERIM RESULTS FOR THE ACROBAT EDGE PHASE 2 TRIAL OF PALTUSOTINE (CRN00808) IN ACROMEGALY PATIENTS AND PROVIDES CORPORATE UPDATEApr 6, 2020
BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic CoughApr 3, 2020
resTORbio Announces Delay of its Ongoing Phase 1b/2a trial of RTB101 in Patients with Parkinson’s Disease Due to COVID-19 Level 4 Alert in New ZealandApr 2, 2020
ORIC PHARMACEUTICALS APPOINTS CHRISTIAN V. KUHLEN, M.D., AS GENERAL COUNSELApr 1, 2020
Ascendis Pharma A/S Reports Full-Year 2019 Financial ResultsApr 1, 2020
Pandion Therapeutics Announces Close of $80 Million Series B FinancingApr 1, 2020
HARPOON THERAPEUTICS APPOINTS TWO NEW MEMBERS TO ITS BOARD OF DIRECTORSApr 1, 2020
Aspen Neuroscience Announces $70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy to Treat Parkinson DiseaseMar 31, 2020
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL AND SPECIALMar 31, 2020
Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPDMar 31, 2020
Health Catalyst Launches Four Additional COVID-19 Solutions and a Modular BundleMar 31, 2020
Xenon Pharmaceuticals Provides Corporate Update in the Context of COVID-19Mar 31, 2020
FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia TherapeuticsMar 30, 2020
Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational ActivitiesMar 30, 2020
Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471, a Unique Fully Human Agonist of CD137Mar 30, 2020
NextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of DirectorsMar 30, 2020
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial ResultsMar 30, 2020
Harmony Biosciences Highlights Publication of Narcolepsy Treatment Scientific Review in Sleep MedicineMar 27, 2020
TELA Bio Announces Fourth Quarter and Full Year 2019 Financial ResultsMar 26, 2020
Prevail Therapeutics Reports Full Year 2019 Financial Results and Business HighlightsMar 25, 2020
89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of DirectorsMar 25, 2020
Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in ChinaMar 25, 2020
BELLUS Health Announces Closing of Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovationsMar 24, 2020
scPharmaceuticals Inc. Reports Fourth Quarter and Year Ended 2019 Financial Results and Provides Business UpdateMar 24, 2020
Health Catalyst Expands COVID-19 Response Support and Provides Infrastructure to Enable Readiness for Future DemandsMar 24, 2020
Alector Reports 2019 Fourth Quarter and Full Year Financial Results and Business HighlightsMar 24, 2020
Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR006 to Slow the Progression of Frontotemporal Dementia with a GRN MutationMar 24, 2020
Glaukos Provides COVID-19 Pandemic UpdateMar 23, 2020
ObsEva Provides Update Related to COVID-19 PandemicMar 23, 2020
Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of DirectorsMar 23, 2020
Fusion Pharmaceuticals Appoints James J. O’Leary, M.D. As Chief Medical OfficerMar 23, 2020
Kimberly Lathroum Joins Arcutis as Vice President of MarketingMar 20, 2020
Verona Pharma plc: Issue of Equity and Total Voting RightsMar 19, 2020
BELLUS Health Announces Completion of Enrollment in Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic CoughMar 18, 2020
89bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateMar 18, 2020
SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039Mar 18, 2020
Alpine Immune Sciences’ ALPN-101 Receives FDA Orphan Drug Designations for the Prevention and Treatment of Acute Graft Versus Host DiseaseMar 17, 2020
Health Catalyst Plans to Support Health System Clients� COVID-19 Response with Three Initial Solutions Focused on Patient Tracking, Public Health Surveillance and Staff Augmentation SupportMar 16, 2020
Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateMar 16, 2020
Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business UpdateMar 16, 2020
TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTSMar 16, 2020
Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque PsoriasisMar 13, 2020
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial ResultsMar 12, 2020
Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business UpdateMar 12, 2020
Selecta Biosciences Reports Fourth Quarter 2019 and Year-End Financial ResultsMar 12, 2020
HARPOON THERAPEUTICS REPORTS FOURTH QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEMar 12, 2020
resTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateMar 12, 2020
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business HighlightsMar 12, 2020
Nabriva Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results and Recent Corporate HighlightsMar 12, 2020
AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19Mar 12, 2020
Sonendo® Appoints Amit Agarwal as Vice President of MarketingMar 12, 2020
X4 Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial ResultsMar 12, 2020
CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial ResultsMar 11, 2020
Silverback Therapeutics Raises $78.5 Million in Oversubscribed Series B FinancingMar 11, 2020
Verrica Pharmaceuticals Secures $55 Million in Loan Facilities Led by Silicon Valley BankMar 10, 2020
KALA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF 16,000,000 SHARES OF COMMON STOCKMar 9, 2020
Xenon Pharmaceuticals Reports 2019 Financial Results and Provides Corporate UpdateMar 9, 2020
CRINETICS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEMar 9, 2020
NeuroPace RNS System Receives FDA Approval for MRI Labeling, Allowing Thousands More Patients to Benefit from Personalized, Data-Driven Epilepsy TreatmentMar 9, 2020
Tricida Hires Robert McKague as Executive Vice President, General Counsel & Chief Compliance OfficerMar 9, 2020
KALA PHARMACEUTICALS ANNOUNCES STATISTICALLY SIGNIFICANT RESULTS FOR PRIMARY AND KEY SECONDARY ENDPOINTS IN STRIDE 3 CLINICAL TRIAL EVALUATING EYSUVIS™ FOR SIGNS AND SYMPTOMS OF DRY EYE DISEASEMar 6, 2020
CTI BioPharma Announces Closing of Rights OfferingMar 6, 2020
Keros Therapeutics Closes $56 Million Series C Financing to Advance its Programs in Hematologic and Musculoskeletal DisordersMar 5, 2020
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial ResultsMar 5, 2020
Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate CommunicationsMar 5, 2020
ObsEva Announces Year End 2019 Financial Results and Business UpdateMar 5, 2020
Passage Bio Appoints Athena Countouriotis to Board of DirectorsMar 4, 2020
Fusion Pharmaceuticals Announces Appointment Of Steven Gannon To Board Of DirectorsMar 3, 2020
Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutationsMar 3, 2020
Sierra Oncology Reports 2019 Year End ResultsMar 2, 2020
Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN MutationMar 2, 2020
ORIC PHARMACEUTICALS APPOINTS MARDI C. DIER TO ITS BOARD OF DIRECTORSFeb 28, 2020
Graybug Vision presents preclinical results for GB-401, a potential sustained-delivery treatment of up to six months for primary open angle glaucoma, at the American Glaucoma Society Annual MeetingFeb 27, 2020
Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate UpdateFeb 27, 2020
BELLUS Health Reports Full Year 2019 Financial Results and Business Highlights on BLU-5937Feb 27, 2020
Passage Bio Announces Pricing of Initial Public OfferingFeb 27, 2020
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial ResultsFeb 27, 2020
MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid TumorsFeb 27, 2020
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL AND SPECIALFeb 27, 2020
Glaukos Corporation Announces Fourth Quarter and Full Year 2019 Financial ResultsFeb 27, 2020
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business UpdateFeb 27, 2020
Tricida Announces Fourth Quarter and Full-Year 2019 Financial ResultsFeb 26, 2020
Numerous Presentations to Showcase Long-Term Efficacy & Safety of Glaukos Technologies at 2020 American Glaucoma Society MeetingFeb 26, 2020
Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for Age-related Macular DegenerationFeb 25, 2020
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results and Provides 2020 GuidanceFeb 24, 2020
Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent MilestonesFeb 20, 2020
Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief Scientific OfficerFeb 19, 2020
resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson’s Disease and Provides Corporate UpdateFeb 18, 2020
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial OfficerFeb 14, 2020
CTI BioPharma Announces Commencement of Rights OfferingFeb 14, 2020
Xenon Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional SharesFeb 14, 2020
Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory ResearchFeb 13, 2020
Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers SymposiumFeb 13, 2020
Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque PsoriasisFeb 12, 2020
Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDAFeb 12, 2020
Kala Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial ResultsFeb 12, 2020
X4 Pharmaceuticals Granted New Composition of Matter Patent for Late-Stage Clinical Candidate MavorixaforFeb 10, 2020
Essa Pharma Announces Multiple Abstracts Accepted For Presentation At Upcoming Medical And Scientific SymposiaFeb 10, 2020
Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome ConferenceFeb 7, 2020
Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular HypertensionFeb 7, 2020
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary SharesFeb 6, 2020
VectivBio Adds Commercial Expertise with the Appointment of Kevin Harris as Chief Commercial OfficerFeb 6, 2020
Imara Appoints Joelle Lufkin, M.P.H., as Senior Vice President of DevelopmentFeb 6, 2020
Fusion Pharmaceuticals Announces Appointment Of Pablo J. Cagnoni, M.D., To Board Of DirectorsFeb 6, 2020
Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to GileadFeb 6, 2020
Sonendo® Appoints Andrew Kirkpatrick as Chief Operating OfficerFeb 5, 2020
Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal DementiaFeb 4, 2020
Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesFeb 4, 2020
TELA Bio Announces Publication of Results from In-Vivo Study Demonstrating Favorable Response to Reinforced Biologics in Hernia RepairFeb 3, 2020
CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe ThrombocytopeniaFeb 3, 2020
Verona Pharma Announces Senior Management ChangesFeb 3, 2020
OrbiMed Announces New General PartnerFeb 3, 2020
Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesFeb 3, 2020
Galecto Appoints Industry Leader Bertil Lindmark, MD, PhD, as Chief Medical OfficerFeb 3, 2020
Inspire Medical Systems, Inc. Announces Medicare Policy Release Dates and New Draft Local Coverage Determination for Remaining RegionFeb 3, 2020
Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMedFeb 1, 2020
Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1/1b Clinical Trial of CPI-818 at the 12th Annual T-Cell Lymphoma ForumJan 30, 2020
Synlogic Appoints Dr. Michael Burgess to its Board of DirectorsJan 29, 2020
TELA Bio Announces Appointment of New Chief Commercial OfficerJan 29, 2020
Verrica Pharmaceuticals Announces the Hiring of Two Vice Presidents to Further Grow its Commercial CapabilitiesJan 28, 2020
Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid TumorsJan 28, 2020
Alector Announces Initiation of Phase 1b Study of AL003 in Alzheimer’s Disease PatientsJan 28, 2020
Passage Bio Appoints Bruce Goldsmith, Ph.D. as Chief Executive OfficerJan 27, 2020
Harmony Biosciences Secures $200 Million Debt FacilityJan 27, 2020
ORIC Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial of ORIC-101 in Combination with XTANDI® for the Treatment of Prostate Cancer in Collaboration with AstellasJan 27, 2020
Alector Announces Proposed Public Offering of Common StockJan 27, 2020
ReViral’s Phase 2a RSV Study publication selected as Editor’s Pick in February 2020 issue of ASM’s Antimicrobial Agents and ChemotherapyJan 24, 2020
Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn's & Colitis Congress ALPN-101 demonstrates efficacy in treatment of chronic inflammatory bowel disease in both in vivo and in vitro modelsJan 23, 2020
Turning Point Therapeutics Names Garry Nicholson to Its Board of DirectorsJan 22, 2020
TigerConnect Names New Chief Technology Officer as it Accelerates Product InnovationJan 22, 2020
Sierra Oncology Announces Reverse Stock SplitJan 22, 2020
Xenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common SharesJan 22, 2020
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary SharesJan 21, 2020
Arcutis Announces ARQ-154 Program for Scalp Psoriasis and Enrollment of First Patient in Phase 2b Clinical TrialJan 18, 2020
Verrica Pharmaceuticals Announces Presentation of Positive Data from New Pooled Analysis of Phase 3 CAMP Trials of VP-102Jan 15, 2020
Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for EYSUVIS™ (KPI-121 0.25%) for Dry Eye DiseaseJan 15, 2020
Patricia Turney Joins Arcutis as Senior Vice President, ManufacturingJan 14, 2020
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell TherapiesJan 14, 2020
Adimab Extends Platform Partnership with Novo NordiskJan 13, 2020
Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple MyelomaJan 13, 2020
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814Jan 13, 2020
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium TherapyJan 13, 2020
Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board (CPPIB)Jan 13, 2020
Turning Point Therapeutics Announces Program Updates and Milestones for 2020Jan 13, 2020
ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People’s Republic of ChinaJan 13, 2020
Adimab Provides 2019 Update on Clinical PipelineJan 13, 2020
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor IndicationsJan 13, 2020
Arcutis Announces Exercise of Option for Exclusive License to Highly Selective JAK1 Inhibitor for All Topical Dermatological Uses in U.S., Canada, Europe and JapanJan 13, 2020
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D LeadershipJan 13, 2020
Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)Jan 13, 2020
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate UpdateJan 12, 2020
Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare ConferenceJan 10, 2020
TERNS PHARMACEUTICALS PRESENTS RESULTS FROM AN ONGOING PHASE 1 CLINICAL TRIAL OF TERN-201, A SSAO INHIBITOR IN DEVELOPMENT FOR NASHJan 10, 2020
Passage Bio Appoints Sandip Kapadia to Board of DirectorsJan 10, 2020
Adimab Provides Year-End Update on 2019 Partnership ActivitiesJan 10, 2020
TELA Bio Announces Preliminary Revenue for Fourth Quarter and Full Year 2019Jan 9, 2020
Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline ProgramsJan 9, 2020
Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular DegenerationJan 9, 2020
Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 MilestonesJan 9, 2020
Aspen Neuroscience Announces Board of Directors and Scientific Advisory BoardJan 9, 2020
Prevail Therapeutics Provides PR001 Program UpdateJan 9, 2020
Turning Point Therapeutics Announces Management TransitionJan 8, 2020
Topical Ocular Formulation of Aerpio Pharmaceutical's AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b TrialJan 8, 2020
Nabriva Therapeutics Receives FDA Acknowledgement of New Drug Application Resubmission for Intravenous CONTEPO™ (fosfomycin) for InjectionJan 8, 2020
Arcutis Announces Enrollment of First Patients in Two Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 as a Potential Once Daily Topical Treatment for Plaque PsoriasisJan 7, 2020
VectivBio Launches with $35M Financing to Bring Best-in-Disease Medicines to Patients with Serious Rare DiseasesJan 7, 2020
Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor RelationsJan 7, 2020
Galecto and PharmAkea merge to create strong clinical-stage company developing first-in-class therapeutics in fibrosis and cancerJan 6, 2020
Turning Point Therapeutics Names Homa Yeganegi Senior Vice President, Project Team Leader and Head of Medical AffairsJan 6, 2020
Alector Initiates First-in-Human Dosing in Phase 1 Study of AL101 for the Treatment of Neurodegenerative DiseasesJan 6, 2020
Arcutis Biotherapeutics Announces Filing of Registration Statement for Proposed Initial Public OfferingJan 6, 2020
Sonendo® Announces Growth Investment from EW Healthcare PartnersDec 31, 2019
HLS Therapeutics Announces Health Canada Approval for Vascepa® to Reduce the Risk of Cardiovascular EventsDec 30, 2019
X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor in Combination with Ibrutinib for the Treatment of Waldenström’s Macroglobulinemia (WM)Dec 30, 2019
Principia Updates PRN1008 Pemphigus Clinical ProgramDec 20, 2019
Nabriva Therapeutics Resubmits New Drug Application for Intravenous CONTEPO™ (fosfomycin) for InjectionDec 20, 2019
Alector Added to the NASDAQ Biotechnology IndexDec 20, 2019
Nabriva Therapeutics Announces $20 Million Registered Direct OfferingDec 13, 2019
Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review CommitteeDec 13, 2019
Alector Showcases Progress in Immuno-Neurology Clinical Programs and Research Portfolio at R&D DayDec 12, 2019
AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe DiseaseDec 12, 2019
Selecta Biosciences Announces $70 Million Private PlacementDec 12, 2019
Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212Dec 11, 2019
Alector Announces Appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as President and Chief Operating OfficerDec 11, 2019
PMV Pharma Appoints Leila Alland, M.D., as Chief Medical OfficerDec 9, 2019
Alpine Immune Sciences Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at the 61st American Society of Hematology Annual MeetingDec 9, 2019
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of LinzagolixDec 9, 2019
CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Benefit in Myelofibrosis Patients with Severe Thrombocytopenia at the 61st American Society of Hematology MeetingDec 8, 2019
Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 BillionDec 7, 2019
Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual MeetingDec 7, 2019
Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 TrialDec 6, 2019
Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) MeetingDec 5, 2019
Alector Announces FDA Fast Track Designation Granted to AL001 for the Treatment of Patients with Frontotemporal DementiaDec 4, 2019
TransMedics’ Organ Care System (OCS™) Technology Used in First U.S. Adult Human Heart Transplants From DCD DonorsDec 3, 2019
Tricida Announces Hiring of Elizabeth Faust, Ph.D., as Senior Vice President of Medical AffairsDec 3, 2019
Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP?A2M4 for the Treatment of Synovial SarcomaNov 27, 2019
ReViral Appoints Lawrence Blatt and Richard N. Kender to its Board of DirectorsNov 26, 2019
X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B WarrantsNov 25, 2019
X4 Pharmaceuticals Announces Proposed Public OfferingNov 21, 2019
Glaukos Completes Acquisition of Avedro, Inc.Nov 21, 2019
Harpoon Therapeutics And Abbvie Announce Licensing And Option Collaboration To Advance Hpn217, Harpoon’s Bcma-Targeting Tritac®, And Expand Existing Discovery CollaborationNov 21, 2019
Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of DirectorsNov 21, 2019
Selecta Biosciences Appoints Carrie S. Cox as Chairman of its Board of DirectorsNov 19, 2019
Verrica Pharmaceuticals Announces Passing of Board of Directors Member Glenn OclassenNov 19, 2019
NextCure Announces Closing of Public OfferingNov 18, 2019
Ascendis Pharma A/S Reports Third Quarter 2019 Financial ResultsNov 18, 2019
Nabriva Therapeutics Commends the CDC on the 2019 Antibiotic Resistance Threats Report, Highlighting the Need for New Antibiotics Aligned with Antibiotic StewardshipNov 18, 2019
Prevail Therapeutics Announces Appointment of Morgan Sheng, Ph.D., to Board of DirectorsNov 18, 2019
Phase 2a Study Published in Antimicrobial Agents and Chemotherapy Shows Potential of Sisunatovir (RV521) to Combat Respiratory Syncytial Virus InfectionNov 16, 2019
Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial SarcomaNov 15, 2019
resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary EndpointNov 14, 2019
Arcutis Appoints Keith Klein as General CounselNov 14, 2019
Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United StatesNov 14, 2019
Tricida Announces Third Quarter 2019 Financial ResultsNov 14, 2019
BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2019Nov 14, 2019
NextCure Announces Pricing of Public Offering of Common StockNov 14, 2019
Verona Pharma plc: PDMR Dealing – Purchase by ChairmanNov 14, 2019
Tricida Announces FDA Acceptance of New Drug Application for VeverimerNov 13, 2019
PMV Pharma Secures $62 Million in Series C Financing To Develop Cancer Drugs Targeting p53Nov 12, 2019
Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial ResultsNov 12, 2019
NextCure Reports Third Quarter 2019 Financial ResultsNov 12, 2019
X4 Pharmaceuticals Receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the Treatment of WHIM SyndromeNov 12, 2019
Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNov 12, 2019
SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business HighlightsNov 12, 2019
Alpine Immune Sciences Presents New ALPN-101 Preclinical Data at the 2019 American College of Rheumatology (ACR) Annual MeetingNov 12, 2019
Alector Reports Recent Business Highlights and Third Quarter 2019 Financial ResultsNov 12, 2019
scPharmaceuticals Inc. Reports Third Quarter 2019 Financial Results and Provides Business UpdateNov 12, 2019
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric PatientsNov 12, 2019
Prevail Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business HighlightsNov 12, 2019
Nabriva Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate HighlightsNov 11, 2019
SI-BONE, Inc. Reports Third Quarter 2019 Financial Results and Updates Full-Year 2019 Revenue GuidanceNov 11, 2019
Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory GoutNov 11, 2019
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC InhibitorNov 11, 2019
89bio Announces Pricing of Upsized Initial Public OfferingNov 11, 2019
Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic IndicationsNov 9, 2019
NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the TrialNov 8, 2019
Selecta Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNov 8, 2019
Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual MeetingNov 8, 2019
Alpine Immune Sciences Presents New Preclinical Data at The Society for Immunotherapy of Cancer's (SITC) 34th Annual MeetingNov 7, 2019
Aerpio Reports Third Quarter 2019 Financial Results and Provides Business UpdateNov 7, 2019
Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary EndpointNov 7, 2019
TELA Bio Announces Pricing of Initial Public Offering of Common StockNov 7, 2019
X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business HighlightsNov 7, 2019
Kala Reports Third Quarter 2019 Financial ResultsNov 7, 2019
ObsEva Announces Third Quarter 2019 Financial ResultsNov 7, 2019
Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNov 6, 2019
Arvinas Announces Proposed Offering of Common StockNov 6, 2019
Verrica Pharmaceuticals Reports Third Quarter 2019 Financial ResultsNov 6, 2019
Arvinas Announces Pricing of Public Offering of Common StockNov 6, 2019
Adaptimmune Reports Third Quarter 2019 Financial Results and Business UpdateNov 6, 2019
Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019Nov 6, 2019
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2019 Financial ResultsNov 6, 2019
Harpoon Therapeutics Reports Third Quarter 2019 Financial Results And Provides Corporate UpdateNov 6, 2019
Alpine Immune Sciences Announces Oral Presentation of ALPN-101 at the 61st American Society of Hematology Annual Meeting and ExpositionNov 6, 2019
Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate HighlightsNov 5, 2019
X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor for the Treatment of Severe Congenital NeutropeniaNov 5, 2019
Inspire Medical Systems, Inc. Announces Third Quarter 2019 Financial Results and Increases 2019 OutlookNov 5, 2019
Synthorx Reports Third Quarter Financial ResultsNov 5, 2019
Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNov 5, 2019
Principia Biopharma reports third quarter financial resultsNov 5, 2019
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019Nov 5, 2019
Silverback Therapeutics to Present Preclinical Data at SITC 34th Annual Meeting Demonstrating SBT6050’s Potential for Robust Single Agent Activity in Tumors Refractory to Checkpoint InhibitionNov 5, 2019
resTORbio Reports Third Quarter 2019 Financial Results and Corporate UpdateNov 4, 2019
CTI BioPharma Reports Third Quarter 2019 Financial ResultsNov 4, 2019
Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNov 4, 2019
Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational ResultsNov 4, 2019
SI-BONE Announces Medicare Physician Payment Increase of 27% for Minimally Invasive SI Joint FusionNov 4, 2019
X4 Pharmaceuticals Appoints Derek Meisner, J.D., as General CounselNov 4, 2019
Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial OfficerNov 1, 2019
ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVFOct 31, 2019
Promentis Pharmaceuticals Announces Positive Results for Phase 2A Study of SXC-2023 Targeting Novel Glutamatergic Mechanism and Completion of Enrollment for Phase 2 Trichotillomania StudyOct 31, 2019
Intellia Therapeutics Announces Third Quarter 2019 Financial ResultsOct 30, 2019
Alpine Immune Sciences Completes Enrollment of Phase I Study of ALPN-101 and Announces Third Quarter Conference CallOct 30, 2019
Arcutis Announces Addition of Three Senior Biopharmaceutical Executives to Management TeamOct 29, 2019
Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual CongressOct 29, 2019
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial ResultsOct 29, 2019
Harpoon Therapeutics Presents Preclinical Data For Hpn328, A Dll3-Targeting T Cell Engager, At Aacr-Nci-Eortc International Conference On Molecular Targets And Cancer TherapeuticsOct 29, 2019
Passage Bio Appoints Richard Morris as Chief Financial OfficerOct 28, 2019
ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at AACR-NCI-EORTC Annual ConferenceOct 28, 2019
ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOct 24, 2019
Arcutis Biotherapeutics Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Phase 3 Program for ARQ-151 for Plaque PsoriasisOct 24, 2019
Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)Oct 24, 2019
Compass Therapeutics to Present Preclinical Data on a Novel PD-1/PD-L1 Bispecific Antibody and from its Proprietary Innate Cell Engager Platform at the 2019 SITC MeetingOct 24, 2019
SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)Oct 23, 2019
Arvinas presents a platform update, including initial data from the first two clinical trials of protac targeted protein degradersOct 23, 2019
Avera eCARE® Selects Tyto Care as an Enterprise Solution for Virtual CareOct 22, 2019
Harpoon therapeutics announces presentation on HPN328 at AACR-NCI-EORTC international conference on molecular targets and cancer therapeuticsOct 22, 2019
Compass Therapeutics Appoints Leading Immuno-Oncology Researchers to Its Immuno-Oncology Scientific Advisory BoardOct 21, 2019
ReViral Announces Appointment of Alan Musso as Chief Financial OfficerOct 21, 2019
Aerpio Pharmaceuticals Announces Review of Strategic AlternativesOct 21, 2019
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in EuropeOct 21, 2019
Arcutis Announces the Completion of $94.5 million Series C FinancingOct 18, 2019
Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology ConferenceOct 18, 2019
ESSA Announces Changes to its Board of DirectorsOct 18, 2019
Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne SufferersOct 17, 2019
Enyo pharma announces multiple EYP001 data presentations at AASLD conferenceOct 17, 2019
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPDOct 16, 2019
Novant Health and Tyto Care Partner to Provide Unique Digital Health OfferingsOct 16, 2019
Natera Announces Pricing of Follow-On OfferingOct 15, 2019
Principia Announces Proposed Public Offering of Common StockOct 15, 2019
Terns pharmaceuticals to present postive preclinical data on fxr agonist TERN-101 at the liver meeting 2019Oct 15, 2019
Principia Announces Positive Preliminary Data of PRN1008 For Immune Thrombocytopenia in Ongoing Phase 1/2 TrialOct 15, 2019
Principia Announces Pricing of Public Offering of Common StockOct 10, 2019
Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle GlaucomaOct 10, 2019
Principia Announces Positive Preliminary Data of PRN1008 From Its Ongoing Phase 2 Part B Trial in PemphigusOct 9, 2019
Arcutis Announces Enrollment of Last Patient in Phase 2a Clinical Trial of ARQ-151 Cream as a Potential Topical Treatment for Atopic DermatitisOct 9, 2019
TigerConnect Recognized as One of the Best Places to Work in Healthcare for the Fifth Consecutive YearOct 9, 2019
Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell TherapiesOct 9, 2019
Verrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical OperationsOct 8, 2019
Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative DiseasesOct 7, 2019
Verrica Pharmaceuticals Announces Leadership Team UpdateOct 5, 2019
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle SocietyOct 3, 2019
Enyo pharma announces move to new corporate headquartersOct 2, 2019
Adicet Bio Raises $80M in Series B FinancingOct 2, 2019
Graybug Vision Initiates Phase 2b (ALTISSIMO) Clinical Trial of GB-102 in Patients with Wet Age-Related Macular DegenerationOct 2, 2019
Arvinas strengthens scientific advisory board with leaders in oncology and neurological disordersOct 2, 2019
resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019Oct 2, 2019
NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating OfficerOct 1, 2019
Bayer and Arvinas unveil targeted protein degradataion joint venture, Oerth BioOct 1, 2019
Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing InvestorsOct 1, 2019
CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe ThrombocytopeniaOct 1, 2019
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial OfficerSep 30, 2019
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMOSep 30, 2019
Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM)Sep 30, 2019
European Respiratory Society International Congress, Madrid 29 September 2019Sep 30, 2019
X4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma PatientsSep 30, 2019
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC InhibitorSep 28, 2019
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 CongressSep 27, 2019
Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical AssociationSep 26, 2019
Inspire Medical Systems, Inc. Announces Additional Draft Local Coverage Determinations Proposing Coverage of Inspire TherapySep 26, 2019
Arbitration Decision Affirms Intellia Therapeutics’ Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 TechnologySep 25, 2019
SI-BONE, Inc. Announces Publication of Five-Year Prospective Study Results on 103 Patients Treated with Triangular Titanium iFuse Implant SystemSep 25, 2019
89bio Announces Dosing of First Patients in NASH Study and Issuance of Composition of Matter PatentSep 24, 2019
European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue SarcomaSep 24, 2019
Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 FranchiseSep 24, 2019
Foundation Medicine and Natera Partner to Advance Personalized Cancer MonitoringSep 23, 2019
Passage Bio Grows Management Team with Chief Medical Officer and General Counsel AppointmentsSep 23, 2019
Adicet Bio Appoints Francesco Galimi, M.D., Ph.D., SVP and Chief Medical OfficerSep 23, 2019
X4 Pharmaceuticals Appoints William E. Aliski to Board of DirectorsSep 19, 2019
Prevail Therapeutics Announces Addition to Russell 2000®, 3000® and Microcap® IndexesSep 18, 2019
Arcutis, Inc.’s Development Program for EczemaSep 18, 2019
Graybug Vision Initiates Clinical Trial in Macular Edema Secondary to Diabetic Macular Edema or Retinal Vein OcclusionSep 18, 2019
X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and DevelopmentSep 18, 2019
scPharmaceuticals Inc. Provides FUROSCIX® Update and Announces Completion of $20.0 Million Term Loan AgreementSep 17, 2019
BELLUS Health Announces Exercise of Over-Allotment Option in Connection With Underwritten Public Offering of Common SharesSep 17, 2019
SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional SharesSep 17, 2019
Xenon Announces Appointment of Shelley McCloskey as Senior Vice President, Human ResourcesSep 17, 2019
Edgewise Therapeutics Closes $50 Million Series B FinancingSep 16, 2019
Verrica Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for VP-102 for the Treatment of Molluscum ContagiosumSep 13, 2019
Gemini Therapeutics Announces Leadership AppointmentSep 13, 2019
Imara Submits Confidential Draft Registration Statement for Proposed Initial Public OfferingSep 12, 2019
Tricida Launches Metabolic Acidosis Insights, an Online Educational Resource for the Healthcare CommunitySep 12, 2019
Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society MeetingSep 12, 2019
SpringWorks Therapeutics Announces Pricing Of Initial Public OfferingSep 11, 2019
Boost Epi-On™ Corneal Cross-Linking Data to Be Presented at the 37th Congress of the ESCRSSep 11, 2019
ObsEva announces new composition of its Executive CommitteeSep 10, 2019
ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial OfficerSep 10, 2019
Prevail Therapeutics Provides Program Update on PR001 in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher DiseaseSep 9, 2019
Enyo Pharma Announces New CFO and Provides Clinical Pipelien UpdateSep 9, 2019
BELLUS Health Closes US$70 Million Public Offering of Common Shares in Canada and the United StatesSep 9, 2019
Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.Sep 9, 2019
Passage Bio Announces New Gene Therapy Development Program for Patients with Charcot-Marie-Tooth Neuropathy Type 2ASep 9, 2019
Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative PainSep 9, 2019
Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year PeriodSep 9, 2019
Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal DementiaSep 9, 2019
United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4Sep 6, 2019
Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant SciencesSep 5, 2019
BELLUS Health Announces Pricing of US$70 Million Public Offering in Canada and the United StatesSep 5, 2019
Turning Point Therapeutics Announces Pricing of Public Offering of Common StockSep 4, 2019
Tricida Announces Submission of New Drug Application for Veverimer for the Treatment of Metabolic Acidosis in Patients with Chronic Kidney DiseaseSep 4, 2019
Selecta Biosciences Appoints Brad Dahms as Chief Financial OfficerSep 4, 2019
Passage Bio Closes $110 Million Series B FinancingSep 4, 2019
Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO DepartureSep 4, 2019
Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM)Sep 3, 2019
SI-BONE, Inc. Announces Wellmark Blue Cross Blue Shield Establishes Positive Coverage for MIS SI Joint Fusion Using iFuseSep 3, 2019
Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC InhibitorSep 3, 2019
Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM SymposiumSep 3, 2019
BELLUS Health Announces the Launch of a US$60 Million Public Offering of Common Shares in Canada and the United States and the Filing of an Application to List Its Common Shares on NasdaqSep 3, 2019
Turning Point Therapeutics Announces Proposed Public Offering of Common StockSep 3, 2019
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVFAug 30, 2019
Principia Biopharma Appoints Shawn Tomasello to its Board of DirectorsAug 30, 2019
SpringWorks Therapeutics Appoints Alan Fuhrman to its Board of DirectorsAug 29, 2019
Inspire Medical Systems, Inc. Announces Additional Draft Local Coverage Determinations Proposing Coverage of Inspire TherapyAug 29, 2019
SpringWorks Therapeutics Receives Breakthrough Therapy Designation for Nirogacestat for the Treatment of Adult Patients with Progressive, Unresectable, Recurrent or Refractory Desmoid TumorsAug 28, 2019
Ascendis Pharma A/S Reports Second Quarter 2019 Financial ResultsAug 27, 2019
ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Process of US$36 MillionAug 27, 2019
Cyrus Biotechnology Offers CryoEM Services based on First-in-class, Peer-reviewed Rosetta Software MethodsAug 27, 2019
Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patientsAug 27, 2019
NeRRe Therapeutics Announces Publication of Positive Results in a Phase 2 Pilot Study of Orvepitant in Chronic Refractory CoughAug 27, 2019
Arvinas announces the initiation of patient dosing in a first-in-human phase 1 study of ARV-471, an estrogen receptor-targeting protac protein degraderAug 27, 2019
Pionyr Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated MacrophagesAug 26, 2019
Inspire Medical Systems, Inc. Announces Draft Local Coverage Determinations Proposing Coverage of Inspire Therapy from Two Regional Medicare AdministratorsAug 26, 2019
BELLUS Health Strengthens Leadership Team with Appointment of Dr. Catherine Bonuccelli, MD as Chief Medical OfficerAug 23, 2019
ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private PlacementAug 22, 2019
Medicare Issues Positive Draft Local Coverage Determination for Natera's Signatera� MRD Test in Colorectal CancerAug 20, 2019
Synlogic Discontinues Development of SYNB1020 to Treat HyperammonemiaAug 20, 2019
Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical ProgramsAug 19, 2019
Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)Aug 16, 2019
Nabriva Therapeutics Provides Update on the Planned Resubmission of the New Drug Application for Intravenous CONTEPO™ (fosfomycin) for InjectionAug 15, 2019
Inspire Medical Systems, Inc. Announces Additional 17.7 Million Covered Lives with Seven New Coverage PoliciesAug 15, 2019
BELLUS Health Announces Share ConsolidationAug 14, 2019
resTORbio Reports Second Quarter 2019 Financial Results and Corporate UpdateAug 14, 2019
Prevail Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business HighlightsAug 13, 2019
Imara Expands Management Team and Strengthens Expertise Across Strategic Functions as it Advances IMR-687 for Sickle Cell Disease and Beta ThalassemiaAug 13, 2019
Inspire Medical Systems, Inc. Announces New Brand Identity and Website to Better Reach Prospective Patients Struggling with Sleep ApneaAug 13, 2019
Alpine Immune Sciences Provides Pipeline Update and Reports Second Quarter 2019 Financial ResultsAug 13, 2019
Passage Bio Announces Launch of Natural History Study to Evaluate Patients with GM1 GangliosidosisAug 13, 2019
Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateAug 12, 2019
Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of DirectorsAug 12, 2019
Alector Reports Recent Business Highlights and Second Quarter 2019 Financial ResultsAug 8, 2019
Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateAug 8, 2019
Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans To Repond with Data from Stride 3 TrialAug 8, 2019
89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASHAug 8, 2019
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial ResultsAug 8, 2019
ORIC Pharmaceuticals Announces Completion of $55 Million Mezzanine Financing to Advance Pipeline of Novel Therapies Targeting Cancer ResistanceAug 8, 2019
Principia biopharma reports second quarter financial resultsAug 8, 2019
Aerpio Reports Second Quarter 2019 Financial Results and Provides Business UpdateAug 8, 2019
Synlogic Reports Second Quarter 2019 Financial Results and Provides Program UpdatesAug 8, 2019
Tricida Announces Second Quarter 2019 Financial ResultsAug 8, 2019
BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2019Aug 8, 2019
Nabriva Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate HighlightsAug 7, 2019
ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLCAug 7, 2019
Avedro, Inc. Announces Second Quarter 2019 Financial ResultsAug 7, 2019
ObsEva Reports Second Quarter 2019 Financial ResultsAug 7, 2019
scPharmaceuticals Inc. Reports Second Quarter 2019 Financial Results and Provides Business UpdateAug 7, 2019
Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency ObesitiesAug 7, 2019
Glaukos and Avedro Announce Definitive Acquisition AgreementAug 7, 2019
Verrica Pharmaceuticals Reports Second Quarter 2019 Financial ResultsAug 7, 2019
Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial ResultsAug 7, 2019
Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s Industry-Leading Gene Therapy Platform in Strategic PartnershipAug 6, 2019
Xenon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateAug 6, 2019
Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate HighlightsAug 6, 2019
Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateAug 6, 2019
Kala Pharmaceuticals Reports Second Quarter 2019 Financial ResultsAug 6, 2019
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019Aug 6, 2019
Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational ResultsAug 6, 2019
SI-BONE, Inc. Reports Second Quarter 2019 Financial ResultsAug 6, 2019
Inspire Medical Systems, Inc. Announces Second Quarter 2019 Financial Results and Increases 2019 OutlookAug 5, 2019
Harpoon Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateAug 5, 2019
Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateAug 5, 2019
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPDAug 1, 2019
Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company UpdateAug 1, 2019
CTI BioPharma Reports Second Quarter 2019 Financial ResultsAug 1, 2019
Compass Therapeutics Appoints Julie Sunderland to Board of DirectorsAug 1, 2019
New Executive Team Announced at AdaptimmuneAug 1, 2019
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial ResultsAug 1, 2019
Adaptimmune Reports Second Quarter 2019 Financial Results and Business UpdateAug 1, 2019
Synthorx Reports Second Quarter Financial ResultsJul 31, 2019
Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid TumorsJul 30, 2019
Principia announces update to ongoing Phase 2 clinical trial in patients with ITPJul 30, 2019
TransMedics Announces Successful Long Distance Retrieval and Transplantation of Donor Lungs from Hawaii Using Organ Care System (OCS�)Jul 30, 2019
Foamix Announces $64 Million Capital Financing Investment by Perceptive Advisors and OrbiMedJul 30, 2019
BELLUS Health Announces First Patient Enrolled in Phase 2 Study of BLU-5937 for the Treatment of Refractory Chronic Cough & Pursuit of Second Indication in Chronic PruritusJul 30, 2019
NeuroPace Appoints Mark Saxton as Vice President of SalesJul 30, 2019
X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM SyndromeJul 29, 2019
Arvinas appoints Ronald Peck, M.D as Chief Medical OfficerJul 29, 2019
Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH Congenital HyperinsulismJul 29, 2019
Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial ResultsJul 29, 2019
Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial OfficerJul 29, 2019
Rhythm Pharmaceuticals Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for Setmelanotide for the Treatment of Bardet-Biedl SyndromeJul 26, 2019
ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022Jul 25, 2019
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company UpdateJul 25, 2019
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLSJul 25, 2019
Passage Bio Expands Executive Management TeamJul 25, 2019
Arvinas strengthens board of directors with addition of Leslie NorwalkJul 25, 2019
Turning Point Therapeutics Names Carol Gallagher, Pharm.D. to its Board of DirectorsJul 25, 2019
Inspire Medical Systems, Inc. Announces Changes to its Board of DirectorsJul 24, 2019
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2019 Financial Results on August 1, 2019Jul 24, 2019
Rhythm Pharmaceuticals Announces Appointment of Stuart Arbuckle to its Board of DirectorsJul 24, 2019
Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 DeficiencyJul 24, 2019
Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707Jul 24, 2019
Health Catalyst Announces Pricing of Initial Public OfferingJul 24, 2019
NeuroPace Announces Michael Favet as CEOJul 23, 2019
Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum DepressionJul 23, 2019
resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory IllnessJul 22, 2019
Arcutis, Inc. Announces Positive Top Line Results for Phase 2b Clinical Trial Evaluating ARQ-151 as a Potential Topical Treatment for Plaque PsoriasisJul 22, 2019
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer CenterJul 19, 2019
Realm Therapeutics plc Update on Company’s Nasdaq ListingJul 18, 2019
Augmedix, powered by Glass, accelerates scaling efforts with the nation’s leading healthcare systemsJul 18, 2019
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE?A4 to Enhance Antitumor ResponsesJul 18, 2019
ViewRay Announces Conference Call and Webcast of Second Quarter 2019 Financial Results to be Held After Market on August 8, 2019Jul 18, 2019
Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon™ CNP in Children with AchondroplasiaJul 18, 2019
CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of MyelofibrosisJul 17, 2019
Rhythm Pharmaceuticals Launches Free Genetic Testing Program for Rare Genetic Disorders of ObesityJul 17, 2019
ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programsJul 17, 2019
X4 Pharmaceuticals and Abbisko Therapeutics Enter into Oncology Development and Commercialization Agreement for Mavorixafor in Greater ChinaJul 17, 2019
SI-BONE To Report Second Quarter 2019 Financial Results on August 6, 2019Jul 17, 2019
ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of NolasibanJul 17, 2019
Alector Announces Data from On-going Phase 1b Trial Demonstrating that AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia PatientsJul 17, 2019
ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine FibroidsJul 16, 2019
ViewRay Announces Appointment of Dr. Gail Wilensky to its Board of DirectorsJul 16, 2019
Crinetics Pharmaceuticals appoints Stephanie Okey to Board of DirectorsJul 16, 2019
SCPHARMACEUTICALS INC. PROVIDES REGULATORY UPDATE ON FUROSCIX®Jul 15, 2019
Selecta Biosciences Appoints Alison Schecter, M.D., as Chief Medical OfficerJul 15, 2019
Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of DevelopmentJul 10, 2019
Pionyr Immunotherapeutics and ProBioGen Initiate a Second Immuno-Oncology Contract Development and Manufacturing ProjectJul 10, 2019
Passage Bio Announces New Dedicated Gene Therapy Manufacturing SuiteJul 10, 2019
NIH Study to Utilize NeuroPace RNS® System for Research on the Brain’s Reward SystemJul 10, 2019
Acutus Medical Announces Addition of Scott Huennekens as Executive Chairman of the BoardJul 9, 2019
Inspire Medical Systems, Inc. Announces UnitedHealthcare Coverage for Inspire Therapy for the Treatment of Obstructive Sleep ApneaJul 9, 2019
ORIC Pharmaceuticals Appoints Lori Friedman, PhD, as Chief Scientific OfficerJul 9, 2019
Inspire Medical Systems, Inc. to Report Second Quarter 2019 Financial Results on August 6, 2019Jul 8, 2019
Compass Therapeutics Announces First Patient Dosed in Phase 1 Trial of CTX-471Jun 27, 2019
Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive OfficerJun 27, 2019
SI-BONE’s iFuse Implant System Surpasses 40,000 ProceduresJun 27, 2019
SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple MyelomaJun 26, 2019
Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common WartsJun 26, 2019
Intellia Therapeutics' Statement on Recent U.S. Patent and Trademark Office Actions Relating to Key CRISPR/Cas9 Genome Editing TechnologyJun 26, 2019
X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM SyndromeJun 25, 2019
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of EnsifentrineJun 25, 2019
Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The LancetJun 24, 2019
Realm Shareholders Approve Scheme of Arrangement for Acquisition by ESSA Pharma Inc. at Court MeetingJun 24, 2019
Nabriva Therapeutics Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application for LefamulinJun 20, 2019
Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical StudyJun 20, 2019
Selecta Biosciences Announces Appointment of Scott D. Myers to Board of DirectorsJun 20, 2019
Acutus Medical Announces $170 Million FinancingJun 19, 2019
Nabriva Therapeutics Submits Type A Meeting Request to FDA for Intravenous CONTEPO™ (fosfomycin) for injectionJun 19, 2019
ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA MeetingJun 19, 2019
Prevail Therapeutics Announces Pricing of Initial Public OfferingJun 19, 2019
Rhythm Pharmaceuticals Announces Election of Jennifer Good to its Board of DirectorsJun 18, 2019
BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase InhibitorJun 18, 2019
Imara Presented Positive, Interim Phase 2a Data on IMR-687 for the Treatment of Sickle Cell Disease at the 24th Congress of the European Hematology AssociationJun 17, 2019
SI-BONE Announces the Addition of Mark Foley and Heyward Donigan to the Board of DirectorsJun 17, 2019
Invitae to Acquire Singular Bio to Help Increase Access to Genetic Screening in Early PregnancyJun 13, 2019
PMV Pharma Appoints Deepika Jalota, Pharm.D. as Senior Vice President and Head of Regulatory AffairsJun 13, 2019
Terns Pharmaceuticals Initiates a Phase 1 Clinical Trial of Tern-101Jun 12, 2019
Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209Jun 12, 2019
X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency DiseaseJun 12, 2019
Selecta Biosciences Presents Full Data from Phase 2 Trial of SEL-212 for Chronic Refractory Gout at EULAR 2019Jun 12, 2019
Invitae Announces ID YOUR IRD Program to Expand Access to Genetic Testing for Inherited Retinal DisordersJun 12, 2019
Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ MedicinesJun 11, 2019
Principia Biopharma Appoints Patrick Machado To Board of DirectorsJun 11, 2019
ReViral Appoints Alex C. Sapir as Chief Executive OfficerJun 10, 2019
Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle GlaucomaJun 7, 2019
Nerre Therapeutics Announces Positive Findings From Phase 2B Study With Orvepitant In Chronic CoughJun 5, 2019
HLS Therapeutics Announces Closing of $50 Million Bought Deal OfferingJun 4, 2019
Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPDJun 4, 2019
ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF OutcomesJun 4, 2019
Prevail Therapeutics Announces IND Active for Phase 1/2 Trial of its Gene Therapy PR001 to Treat Parkinson’s Disease Patients with GBA1 MutationsJun 3, 2019
SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1Jun 3, 2019
Invitae introduces new service to make it easier for consumers to receive the medical genetic testing that experts trustJun 3, 2019
Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis PatientsJun 3, 2019
TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold StorageJun 3, 2019
ARQ-151 Atopic Dermatitis P2a Trial InitiatedJun 3, 2019
Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 DeficiencyJun 3, 2019
Alpine Immune Sciences Appoints Biopharma Veteran Wayne Gombotz as Chief Technology OfficerJun 2, 2019
Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual MeetingMay 31, 2019
Research from Invitae Demonstrates the Importance of Germline Multigene Panel Testing in Guiding Therapy for Expanding Groups of Cancer PatientsMay 31, 2019
Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung CancerMay 30, 2019
Passage Bio Announces Third Gene Therapy Development Program in Krabbe Disease and Supports Million Dreams Fundraising GalaMay 30, 2019
Ascendis Pharma A/S Reports First Quarter 2019 Financial ResultsMay 29, 2019
Cyrus Biotechnology Integrates DNA/RNA support into its Rosetta-based Protein Design PlatformMay 29, 2019
Audentes Therapeutics Announces Changes to Senior Management TeamMay 29, 2019
Imara Announces FDA Fast Track Designation for IMR-687 for the Treatment of Sickle Cell DiseaseMay 22, 2019
89bio Reports Positive Top-line Data from Phase 1 Single-Ascending Dose Clinical Trial of BIO89-100, an Investigational Medicine for NASHMay 22, 2019
Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid TumorsMay 22, 2019
World's First MRIdian Center Treats 1,000th Patient with MRI-Guided Radiation TherapyMay 22, 2019
Tyto Care Joins Epic App Orchard to Offer One-of-a-kind Integrated Telehealth Service to Patients and Health ProvidersMay 21, 2019
Crinetics Pharmaceuticals Initiates Phase 1 Study Of CRN01941 For The Treatment Of Neuroendocrine TumorsMay 21, 2019
BELLUS Health Presents Phase 1 Data for BLU-5937, its Lead Product Candidate for the Treatment of Refractory Chronic Cough, at the American Thoracic Society International ConferenceMay 21, 2019
Merck to Acquire Peloton Therapeutics, Bolstering Oncology PipelineMay 20, 2019
Principia Presents Phase 1 Data Of Prn1371 In Patients With Metastatic Bladder CancerMay 20, 2019
resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections in Patients 65 Years of Age and Older with AsthmaMay 20, 2019
Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon™ hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth HormoneMay 20, 2019
SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid TumorsMay 20, 2019
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International ConferenceMay 16, 2019
Agreement Reached for ESSA Pharma to Acquire Realm TherapeuticsMay 16, 2019
Prevail Therapeutics Announces Executive Team Promotion and Appointments to Board of DirectorsMay 16, 2019
Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA AbstractsMay 15, 2019
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell ProductsMay 15, 2019
Turning Point Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TPX-0022, A Novel MET/CSF1R/SRC InhibitorMay 15, 2019
resTORbio Reports First Quarter 2019 Financial Results and Corporate UpdateMay 15, 2019
TigerConnect Names Sarah Shillington SVP of Client SuccessMay 15, 2019
X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s MacroglobulinemiaMay 14, 2019
Principia Biopharma Announces First Patient Dosed In Sanofi’s Phase 2b Trial Of SAR442168 In Multiple Sclerosis, Triggering $30 Million MilestoneMay 14, 2019
Turning Point Therapeutics Names Biotech Veteran Patrick Machado, J.D. To Its Board Of Directors.May 14, 2019
resTORbio Appoints Lloyd Klickstein, M.D., Ph.D., as Chief Scientific OfficerMay 14, 2019
ReViral to Present Data Showing Absence of Clinical Resistance in Volunteers Infected with RSV then Treated with Sisunatovir (RV521)May 13, 2019
Alector Reports Recent Business Highlights and First Quarter 2019 Financial ResultsMay 13, 2019
Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results And Provides Corporate UpdateMay 13, 2019
ORIC Pharmaceuticals Announces Initiation of Phase 1b Study with ORIC-101 in Patients with CancerMay 10, 2019
Nabriva Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate HighlightsMay 9, 2019
ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and EuropeMay 9, 2019
Harpoon Therapeutics Reports First Quarter 2019 Financial Results And Provides Corporate UpdateMay 9, 2019
Avedro, Inc. Announces First Quarter 2019 Financial ResultsMay 9, 2019
Selecta Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate UpdateMay 9, 2019
ObsEva Reports First Quarter 2019 Financial ResultsMay 9, 2019
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2019 Financial ResultsMay 9, 2019
resTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory IllnessMay 9, 2019
Aerpio Reports First Quarter 2019 Financial Results and Provides Business UpdateMay 9, 2019
Synlogic Reports First Quarter 2019 Financial Results and Provides Business UpdateMay 9, 2019
NeuroPace Shares Positive Data from Studies of the RNS System at the American Academy of Neurology 2019 Annual MeetingMay 9, 2019
Kala Pharmaceuticals Reports First Quarter 2019 Financial ResultsMay 9, 2019
Acutus Medical Expands AFib Offerings; Announces Strategic Acquisition and New Partnerships in Monitoring and TherapyMay 8, 2019
Constellation Pharmaceuticals Announces First-Quarter 2019 Financial ResultsMay 8, 2019
Adimab Announces Antibody Discovery Platform Transfer with TakedaMay 8, 2019
Nabriva Therapeutics Announces Submission of Marketing Authorization Application for Lefamulin to Treat Community-Acquired Pneumonia in Adults by European Medicines AgencyMay 8, 2019
Adimab Announces Multi-Target Expansion for the Discovery of Antibodies with Another Global Pharma PartnerMay 8, 2019
SI-BONE, Inc. Reports First Quarter 2019 Financial ResultsMay 8, 2019
Tricida Announces First Quarter 2019 Financial ResultsMay 8, 2019
BELLUS Health Provides Update on Its Chronic Cough Drug Candidate BLU-5937 and Reports Financial and Operating Results for the First Quarter Ended March 31, 2019May 8, 2019
scPharmaceuticals Inc. Reports First Quarter 2019 Financial Results and Provides Business UpdateMay 8, 2019
Adimab Expands Research Agreement with RegeneronMay 7, 2019
Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-YearMay 7, 2019
Principia Biopharma Reports First Quarter Financial ResultsMay 7, 2019
Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate HighlightsMay 7, 2019
Kyn Therapeutics Strengthens Leadership Team with Key AppointmentsMay 7, 2019
Verrica Pharmaceuticals Reports First Quarter 2019 Financial ResultsMay 7, 2019
Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate UpdateMay 7, 2019
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019May 7, 2019
Signatera� Blood Test Detects Bladder Cancer Relapse Up to Eight Months Earlier Than Current Clinical StandardsMay 7, 2019
Peloton Therapeutics Appoints Timothy P. Coughlin and Thilo Schroeder, Ph.D. to its Board of DirectorsMay 7, 2019
Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate UpdateMay 7, 2019
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 TrialsMay 6, 2019
Inspire Medical Systems, Inc. Announces Additional 11.2 Million Covered Lives with New Blue Cross Blue Shield Coverage PoliciesMay 6, 2019
Adaptimmune Reports First Quarter 2019 Financial ResultsMay 6, 2019
Turning Point Therapeutics And Almac Diagnostic Services Announce Approval Of An Investigational Device Exemption For The Companion Diagnostic Assay To The Registrational TRIDENT-1 Clinical StudyMay 6, 2019
Alector Announces First Alzheimer’s Disease Patient Dosed in Phase 1b Study of AL002May 6, 2019
TransMedics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 6, 2019
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid TumorsMay 3, 2019
Rhythm Pharmaceuticals Reports First Quarter 2019 Financial ResultsMay 2, 2019
Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company UpdateMay 2, 2019
Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human SubjectsMay 2, 2019
CTI BioPharma Reports First Quarter 2019 Financial ResultsMay 2, 2019
ViewRay Reports First Quarter 2019 ResultsMay 1, 2019
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell TherapyMay 1, 2019
Avedro Completes Enrollment in Pivotal U.S. Phase 3 Epi-On Corneal Cross-Linking Clinical Trial for Progressive KeratoconusMay 1, 2019
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial ResultsApr 30, 2019
Arcutis, Inc. Announces Board of DirectorsApr 30, 2019
Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for Intravenous CONTEPO™ (fosfomycin) for injectionApr 30, 2019
Synlogic Presents Data Describing a Solid Oral Formulation Process for Synthetic Biotic™ aMedicine SYNB1618 for the Treatment of PKU at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)Apr 30, 2019
Adicet Bio Appoints Anil Singhal Chief Executive OfficerApr 30, 2019
Synthorx Reports First Quarter Financial ResultsApr 29, 2019
Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell TherapyApr 29, 2019
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVFApr 26, 2019
Acutus Medical’s New Contact Mapping Software Receives CE MarkApr 25, 2019
TELA Bio® Appoints Kurt Azarbarzin Chairman of Board of DirectorsApr 24, 2019
Ascendis Pharma A/S Announces Presentations Related to Rare Disease Endocrinology Pipeline at Upcoming Medical ConferencesApr 24, 2019
X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical OfficerApr 23, 2019
Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing FacilityApr 22, 2019
Turning Point Therapeutics Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional SharesApr 18, 2019
Principia Bipharma Appoints Shao-Lee Lin Md PhD to Board of DirectorsApr 18, 2019
Alpine Immune Science Appoints Stanford Peng to President and Head of Research and DevelopmentApr 18, 2019
ViewRay Partners with Leading Canadian Distributor to Bring MRI-guided Radiation Therapy to CanadaApr 18, 2019
TELA Bio® Announces 510(k) Clearance for Restella™ Reconstructive BioScaffolds for Reconstructive SurgeryApr 18, 2019
Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T Cell Engager (HPN536) in Phase 1/2A Clinical Trial for Ovarian and Other Solid Tumor CancersApr 17, 2019
Alector Announces First Frontotemporal Dementia Patient Dosed in Phase 1b Study of AL001Apr 17, 2019
ViewRay Partners with Largest Independent Distributor in Australia and New Zealand to Bring Benefits of MRI-Guided Radiation Therapy to the RegionApr 16, 2019
Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual MeetingApr 16, 2019
Turning Point Therapeutics Announces Pricing Of Initial Public OfferingApr 16, 2019
Inspire Medical Systems, Inc. Announces the 5,000th Patient to Receive Inspire TherapyApr 15, 2019
SI-BONE, Inc. Announces FDA Clearance of iFuse Bedrock™ Novel Spinopelvic Fixation TechnologyApr 12, 2019
X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A WarrantsApr 11, 2019
ViewRay Announces Publication of Retrospective Study on MR-guided Radiation Treatment for Locally Advanced Pancreatic CancerApr 11, 2019
Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.Apr 11, 2019
X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A WarrantsApr 10, 2019
Realm Therapeutics Announces 2018 Annual Report Available and Form 20-F FilingApr 10, 2019
Imara Appoints Chief Financial & Chief Operating OfficerApr 9, 2019
Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.Apr 9, 2019
Synlogic Appoints Scott Plevy M.D. as Chief Scientific OfficerApr 9, 2019
Peloton Therapeutics Announces Completion of Enrollment in Phase 2 Trial of PT2977 for Treatment of von Hippel-Lindau Disease-associated Renal Cell CarcinomaApr 9, 2019
Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate EnsifentrineApr 8, 2019
Inspire Medical Systems, Inc. Announces Three New Positive Coverage Policies Issued by Blue Cross Blue Shield PlansApr 8, 2019
Tricida Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesApr 8, 2019
Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic DystrophyApr 8, 2019
Turning Point Therapeutics Appoints Annette North As Executive Vice President And General CounselApr 8, 2019
https://www.reviral.co.uk/news/45/48/ReViral-Announces-Grant-of-Key-US-Composition-of-Matter-Patent-For-Their-Respiratory-Syncytial-Virus-inhibitor-programme.htmlApr 7, 2019
Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic DisordersApr 5, 2019
Realm Therapeutics Announces Receipt of Nasdaq Listing Determination and Requests HearingApr 5, 2019
Avedro Reaches Reimbursement Milestone for Its FDA-Approved Procedure for Progressive KeratoconusApr 4, 2019
Grant of Options and RSUs and PDMR DealingsApr 3, 2019
Ascendis Pharma A/S Reports Full Year 2018 Financial ResultsApr 3, 2019
Sonendo® to Launch the GentleWave® System in Canada at AAE 2019Apr 3, 2019
Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019Apr 3, 2019
Tricida Announces Pricing of Public Offering of Common StockApr 3, 2019
BELLUS Health Announces Clearance of U.S. IND for BLU-5937 Phase 2 Study in Chronic Cough PatientsApr 2, 2019
resTORbio Announces Initiation of Phase 1b/2a Trial of RTB101 in Parkinson’s DiseaseApr 2, 2019
ORIC Pharmaceuticals Presents Evidence of Glucocorticoid Receptor-Medicated Cancer Treatment Resistance at the AACR Annual MeetingApr 2, 2019
Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) MeetingApr 2, 2019
X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of DirectorsApr 1, 2019
Tricida Announces Proposed Public Offering of Common StockApr 1, 2019
SpringWorks Therapeutics Completes $125 Million Series B FinancingApr 1, 2019
Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual MeetingApr 1, 2019
Turning Point Therapeutics’ Kinase Inhibitors Show High Potency Against Targeted Oncogene Drivers And Their MutationsApr 1, 2019
Happy April 1! Announcing Cyrus ROSVAC-4!Apr 1, 2019
X4 Pharmaceuticals Provides Business and Clinical Development UpdateApr 1, 2019
Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR MeetingApr 1, 2019
Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B FinancingApr 1, 2019
Peloton Therapeutics Announces Clinical Data Update for PT2977 at European International Kidney Cancer SymposiumApr 1, 2019
Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019Apr 1, 2019
Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial OfficerApr 1, 2019
Alector Initiates Phase 1 Trial of AL003 for the Treatment of Patients with Alzheimer’s DiseaseMar 29, 2019
Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management TeamMar 28, 2019
Tricida Announces Positive Results From Long-Term Clinical Trial of TRC101 in Patients With CKD and Metabolic AcidosisMar 28, 2019
Tricida Announces Fourth Quarter and Full-Year 2018 Financial ResultsMar 28, 2019
Tricida Announces $200 Million Debt Facility With Hercules CapitalMar 28, 2019
Rhythm Pharmaceuticals Announces Promising Clinical Data in MC4R Pathway Heterozygous Obesity and Strategy for Further DevelopmentMar 27, 2019
Imara Appoints Chief Medical OfficerMar 26, 2019
Alector Reports Recent Business Highlights and Fourth Quarter and Full Year 2018 Financial ResultsMar 25, 2019
Turning Point Therapeutics Appoints Jim Mazzola to Lead Corporate Communication and Investor RelationsMar 25, 2019
Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-LifeMar 24, 2019
Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon™ hGH to a Daily Growth HormoneMar 22, 2019
resTORbio, Inc. Announces Closing Public Offering of Common StockMar 22, 2019
2018 Annual Report and Accounts and Notice of AGMMar 21, 2019
scPharmaceuticals Inc. Reports Fourth Quarter and Year Ended 2018 Financial Results and Provides Business UpdateMar 21, 2019
Sonendo® Announces Three Key HiresMar 21, 2019
Dr. Martin Edwards Joins Verona Pharma as Non-Executive DirectorMar 21, 2019
Avedro, Inc. Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Full Year 2019 Financial OutlookMar 21, 2019
Turning Point Therapeutics Files Registration Statement for Proposed Initial Public OfferingMar 19, 2019
Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for AcromegalyMar 19, 2019
Principia Biopharma Reports Fourth Quarter and Full Year 2018 Financial ResultsMar 18, 2019
resTORbio Reports Fourth Quarter and Full Year 2018 Financial ResultsMar 18, 2019
Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial ResultsMar 18, 2019
Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic RetinopathyMar 18, 2019
Crinetics Pharmaceuticals Appoints Gina Ford, RPH, MBA, as Vice President, Corporate Strategy and Commercial PlanningMar 18, 2019
Imara Closes a $63MM Series B Cross-Over FinancingMar 18, 2019
resTORbio Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Global Phase 3 Program for RTB101Mar 17, 2019
Prevail Therapeutics Secures $50 Million in Series B Financing to Advance Pipeline of Gene Therapies for Neurodegenerative DiseasesMar 15, 2019
Stereotaxis and Acutus Medical Combine Robotic Precision and High-Resolution Imaging to Treat Arrhythmias in First Integrated ProceduresMar 15, 2019
Selecta Biosciences Announces Fourth Quarter and Year End 2018 Financial Results and Provides Corporate UpdateMar 14, 2019
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate UpdateMar 14, 2019
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial ResultsMar 14, 2019
ViewRay Reports Fourth Quarter and Full Year 2018 ResultsMar 14, 2019
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019Mar 13, 2019
CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent HighlightsMar 13, 2019
Crinetics Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Corporate UpdateMar 13, 2019
Avedro, Inc. Announces Appointment of Patrick B. Jacques as Vice President of SalesMar 13, 2019
ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019Mar 13, 2019
X4 Pharmaceuticals Completes Merger with ArsanisMar 12, 2019
Synlogic Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business UpdateMar 12, 2019
Nabriva Therapeutics Reports 2018 Financial Results and Recent Corporate HighlightsMar 11, 2019
TELA Bio® Announces Multiple Presentations at American Hernia Society Annual Meeting in Las VegasMar 11, 2019
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial ResultsMar 11, 2019
Marinus Pharmaceuticals Provides Business Update and 2018 Financial ResultsMar 11, 2019
Tricida Announces Publication of Positive TRC101 Pivotal Trial Results in The LancetMar 11, 2019
Principia Biopharma Reacquires Rights to Oral Immunoproteasome ProgramMar 8, 2019
Sublimity Therapeutics to Present Positive Data for Ulcerative Colitis Drug CandidateMar 8, 2019
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial ResultsMar 7, 2019
Verrica Reports Fourth Quarter and Full Year 2018 Financial ResultsMar 7, 2019
SI-BONE, Inc. Reports Fourth Quarter and Full Year 2018 Financial ResultsMar 7, 2019
Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business UpdateMar 7, 2019
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate HighlightsMar 6, 2019
SI-BONE, Inc. Announces Journal of Bone and Joint Surgery (JBJS) Publishes 2-Year Results from iMIA, a European Multicenter Randomized Controlled Trial (RCT) of SI Joint Fusion with iFuse Implant System® vs Conservative CareMar 6, 2019
Synlogic Announces Achievement of Milestone in Collaboration to Develop Synthetic Biotic™ Medicines to Treat Inflammatory Bowel DiseaseMar 6, 2019
Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related EpilepsyMar 6, 2019
Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common StockMar 6, 2019
Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate UpdateMar 5, 2019
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSsMar 5, 2019
Cyrus Biotechnology Announces Release of Antibody Structure Prediction Software for Biologics Drug Development and DiscoveryMar 5, 2019
Aerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business UpdateMar 5, 2019
ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business UpdateMar 4, 2019
Inspire Medical Systems, Inc. Announces Five New Positive Coverage Policies Issued by Blue Cross Blue Shield PlansMar 4, 2019
Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPDMar 4, 2019
NextCure and Yale Publish Nature Medicine Paper Detailing Novel Immunomedicine Target Siglec-15Mar 4, 2019
Invitae Announces Proposed Public Offering of Common StockMar 4, 2019
Fusion Pharmaceuticals Announces Appointment Of John J. Crowley As Chief Financial OfficerMar 4, 2019
Constellation Pharmaceuticals Appoints Jessica Christo as Chief Product Development OfficerMar 4, 2019
ORIC Pharmaceuticals Appoints Edna Chow Maneval, PhD, as Senior Vice President of Clinical DevelopmentMar 4, 2019
Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone DeficiencyMar 2, 2019
Verrica Pharmaceuticals Presents Positive Results from Two Phase 3 Clinical Trials of VP-102 in Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology MeetingMar 2, 2019
Principia Biopharma Announces Positive Data From Phase 2 Pemphigus Vulgaris Trial At 2019 American Academy Of Dermatology Annual Meeting In Late-Breaking PresentationMar 1, 2019
Principia Biopharma Presents Phase 1 Clinical Data From CNS Penetrating BTK Inhibitor Candidate PRN2246/SAR442168 at ACTRIMS 2019Feb 28, 2019
Sierra Oncology Reports 2018 Year End ResultsFeb 28, 2019
Audentes Therapeutics Recognizes Rare Disease Day by Launching """"Be Bold for Courageous Patients"""" Program to Support Patients Living with Rare DiseasesFeb 28, 2019
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for AchondroplasiaFeb 27, 2019
Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate UpdateFeb 27, 2019
Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical DataFeb 27, 2019
CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business UpdateFeb 27, 2019
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial ResultsFeb 26, 2019
ReViral Ltd Appoints Seth Hetherington as Chief Medical Officer as it Prepares its Lead RSV Candidate to Enter Pediatric Phase IIa Clinical TrialsFeb 26, 2019
Marinus Announces Leadership TransitionFeb 26, 2019
Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development UpdateFeb 26, 2019
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2018 Financial ResultsFeb 25, 2019
Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease PortfolioFeb 22, 2019
Kala Pharmaceuticals Reports Inducement Grand Under NASDAQ Listing Rule 5635©(4)Feb 21, 2019
ViewRay Announces FDA 510(k) Clearance for Advancements in MRI and Functional Imaging Technologies for MRIdian MRI-Guided Radiation Therapy SystemFeb 21, 2019
BELLUS Health Presents 2018 Highlights and 2019 Corporate PlanFeb 20, 2019
Constellation Pharmaceuticals Announces Appointment to Board of DirectorsFeb 20, 2019
Peloton Therapeutics Secures $150 Million in Series E FinancingFeb 19, 2019
Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018Feb 19, 2019
Alpine Immune Sciences Presents Preclinical ALPN-101 GvHD Data at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings)Feb 19, 2019
Modis Therapeutics Announces that MT1621 Receives Breakthrough Therapy Designation from FDA For the Treatment of TK2 DeficiencyFeb 19, 2019
Nabriva Therapeutics Announces Acceptance of New Drug Applications by the FDA for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in AdultsFeb 13, 2019
Avedro Announces Pricing of Initial Public OfferingFeb 12, 2019
Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information in Early PregnancyFeb 12, 2019
Synlogic Appoints Patricia N. Hurter, Ph.D. to Board of DirectorsFeb 12, 2019
NeuroPace Announces New Category I CPT Code from AMA for Electrocorticography from an Implanted Brain NeurostimulatorFeb 11, 2019
Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with HypoparathyroidismFeb 11, 2019
Clementia Granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans ProgressivaFeb 11, 2019
CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®Feb 11, 2019
Alpine Immune Sciences Announces First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program ALPN-101Feb 7, 2019
Harpoon Therapeutics Announces Pricing of Initial Public OfferingFeb 7, 2019
Sublimity Therapeutics Presents Encouraging New Efficacy Data at the 2019 Crohn's & Colitis CongressFeb 7, 2019
Health Catalyst Secures up to $100 Million with Financing Led By OrbiMedFeb 7, 2019
Alector Announces Pricing of Initial Public OfferingFeb 6, 2019
HLS Therapeutics Announces Graduation to the Toronto Stock ExchangeFeb 6, 2019
Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public OfferingFeb 6, 2019
Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs�CPI-444 and CPI-006 at Immuno-Oncology 360� ConferenceFeb 6, 2019
resTORbio Appoints Erkan Baloglu, Ph.D., M.B.A., as Vice President of Drug Discovery and Medicinal ChemistryFeb 5, 2019
Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer Pharmaceutical Industry Veteran and Former Worldwide Business Franchise Head of Ophthalmology at NovartisFeb 5, 2019
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Feb 5, 2019
Aeglea BioTherapeutics Announces Proposed Public Offering of Common StockFeb 4, 2019
SI-BONE, Inc. Announces Additional Exclusive Coverage Policies for iFuseFeb 4, 2019
Kyn Therapeutics Appoints Douglas Carlson as Chief Financial OfficerFeb 4, 2019
Avedro Launches Initial Public OfferingFeb 1, 2019
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development UpdateJan 31, 2019
Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT DesignationJan 29, 2019
scPharmaceuticals Inc. Announces Development Agreement with West Pharmaceutical Services for Next-Generation FUROSCIX� On-Body InfusorJan 28, 2019
Xenon Provides Key Regulatory Updates on XEN007 and XEN1101Jan 28, 2019
Corvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical OfficerJan 24, 2019
Intellia Therapeutics Names Fred Cohen, M.D., to Board of DirectorsJan 24, 2019
TELA Bio Announces First Patient in Europe Treated with OviTex® Reinforced BioScaffoldsJan 23, 2019
Selecta Biosciences Announces Pricing of Public Offering of Common StockJan 23, 2019
ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG TrialJan 22, 2019
World's First MRIdian Center Celebrates Five Years of MRI-Guided Radiation TreatmentsJan 22, 2019
Selecta Biosciences Announces Proposed Public Offering of Common StockJan 21, 2019
Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019Jan 18, 2019
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology TherapiesJan 18, 2019
Kala Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635C(4)Jan 17, 2019
Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic MechanismJan 17, 2019
Tricida Announces Hiring of Susannah Cantrell, Ph.D., as Chief Commercial OfficerJan 17, 2019
Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic RetinopathyJan 17, 2019
Terns Pharmaceuticals Announces the Appointment of Erin Quirk, M.D., as Chief Medical OfficerJan 17, 2019
Proteus Digital Health® Launches Digital Oncology Medicines to Improve Patient OutcomesJan 16, 2019
Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogic’s Synthetic Biotic™ Medicine in Development as a Potential Treatment for HyperammonemiaJan 16, 2019
Inspire Medical Systems, Inc. Announces a Positive Coverage Policy Issued by Horizon Blue Cross Blue Shield of New JerseyJan 16, 2019
Alpine Immune Sciences Announces $25 Million Private PlacementJan 14, 2019
Nabriva Therapeutics Provides Update on PDUFA Date for Intravenous CONTEPO™Jan 14, 2019
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance TreatmentJan 14, 2019
Inspire Medical Systems, Inc. Announces First BCBS Coverage Policy following Evidence Street’s Positive Therapy Indication SummaryJan 10, 2019
TELA Bio begins commercialization for Large Size OviTex® Reinforced BioScaffolds for Hernia Repair and Abdominal Wall Reconstruction after Aroa Biosurgery receives 510k clearance.Jan 10, 2019
Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell LymphomasJan 9, 2019
Adimab Provides 2018 Update on Clinical PipelineJan 9, 2019
Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554Jan 9, 2019
Venus Medtech Announces Agreement to Acquire Keystone Heart, LTDJan 8, 2019
Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine AntagonistJan 8, 2019
Dr. Mary Kerr CEO NeRRe Therapeutics Presents at the Biotech Showcase, San FranciscoJan 8, 2019
Adimab Provides Year-End Update on 2018 Partnership ActivitiesJan 7, 2019
Sublimity Therapeutics Receives Investigational New Drug (IND) Clearance from U.S. Food and Drug Administration (FDA)Jan 7, 2019
Verrica Appoints Neil D. DeHenes as Vice President of Distribution, Trade and Channel StrategyJan 7, 2019
Inspire Medical Systems, Inc. Announces a Positive Coverage Policy Issued by Horizon Blue Cross Blue Shield of New JerseyJan 7, 2019
Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key PrioritiesJan 7, 2019
Gemini Therapeutics Announces the Initiation of CLARITY, a Disease Registry and Natural History Study of Subjects with Dry AMD and High-Risk GenotypesJan 7, 2019
ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2018 ResultsJan 7, 2019
KaNDy Therapeutics Announces the Appointmetn of Andrew Kay as Independent Chairman of the BoardJan 7, 2019
Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple ApproachesJan 7, 2019
Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety ReviewsJan 7, 2019
Invitae reports 2018 preliminary financial results, delivering more than 100% volume and revenue growth in 2018; projects sustained growth in expanding markets through 2019 and beyondJan 7, 2019
SI-BONE Reports Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2018Jan 7, 2019
Kala Pharmaceuticals Announces the Launch of Inveltys and the Hiring of a Specialty Ophthalmology Sales OrganizationJan 7, 2019
Adimab Partner Innovent Receives Product Approval for PD-1 Antibody for Hodgkin's LymphomaJan 7, 2019
Cyrus Bio announces full release of rapid and accurate protein mutational free energy tool in Cyrus BenchJan 6, 2019
Xenon Pharmaceuticals Outlines 2019 Key MilestonesJan 4, 2019
Nabriva Therapeutics Provides Update on PDUFA Date for Intravenous CONTEPO™Jan 4, 2019
ViewRay Announces First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial for Locally Advanced Pancreatic CancerJan 4, 2019
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Jan 3, 2019
E-Scape Bio Appoints Dr. Carrolee Barlow as Chief Medical OfficerJan 3, 2019
Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum ContagiosumJan 3, 2019
Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554Jan 3, 2019
Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2019 CatalystsJan 3, 2019
Selecta Biosciences Expands Potential for ImmTOR™ Platform and Streamlined Structure Under Leadership of New CEO, Carsten Brunn, Ph.D.Jan 3, 2019
Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead ProgramsJan 3, 2019
Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial OfficerJan 2, 2019
Nora Brennan Joins TELA Bio® as Chief Financial OfficerJan 2, 2019
Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data From Its HPN424 Phase 1 Trial in Prostate Cancer